The QualityStocks Daily Wednesday, February 13th, 2019

Today's Top 3 StockMarketWatch

MarketClub Analysis (SOLO) +220.74%

StocksToBuyNow (ZNGY) +100.00%

QualityStocks (PTX) +52.94%

The QualityStocks Daily Stock List

PUDO, Inc. (PDPTF)

Penny Stock Tweets, Stockwatch, Capital Cube, Financial Content, MarketWatch, Infront Analytics, YCharts, The Street, InvestorsHub, Market Screener, Stockreads, Penny Stock Hub, GuruFocus, Investorx, The Wall Street Analyzer, Stockhouse, Morningstar, Wallet Investor, Barchart, Otc.watch, and 4-Traders reported earlier on PUDO, Inc. (PDPTF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

PUDO, Inc. is North America's first carrier-neutral Pick-Up Drop-Off Network. It is developing North America's only carrier-neutral parcel pick-up/drop-off technology and logistics network as a way of solving the last-mile parcel-traffic-control gridlock. Recently, the Company was named one of the Top 20 most innovative public technology companies by the Canadian Innovation Exchange. Established in 2015, PUDO is headquartered in Mississauga, Ontario.

PUDO’s team of logistics and parcel traffic management experts have created a market intelligence and trends driven solution. This comprises carrier-neutral plug-and-play technology for desktop and mobile, plus a strategically located network of parcel pick-up and drop-off PUDOpoints for pay-as-you-go use by all players within the e-commerce environment.

The Company's technology and network virtually eliminates expenses associated with second-attempt deliveries, un-attended parcel theft and spoilage, and mismanaged reverse logistics on returns. PUDO’s technology and network provides carriers, retailers, and consumers with needed cost controls, choice, and convenience.

A PUDO Point™ is a convenience store usually within minutes of one’s location. It will accept one’s shipments for them and be there when they are ready to pick them up. There are thousands of PUDO-authorized dealer pickup and drop-off locations across the U.S. and Canada.

Concerning e-commerce and return logistics, PUDO offers complete and cost-effective return logistics programs for its eRetailers and corporations. The Company has a distributed and remote work force across the U.S. and Canada.

PUDO has signed an Agreement with global third-party logistics company Landmark Global, Inc. (LGI), part of the bpost group, to undertake a mutually beneficial arrangement for LGI and its customers to use PUDO's Network of parcel pick-up and drop-off locations, to enhance the last-mile e-commerce parcel delivery experience in Canada on Landmark Global's new Sprintstar network. Using the PUDO network of services, Landmark Global will be able to expand its Sprintstar service to many communities not previously served.

Last month, PUDO announced that it filed interim financial results (unaudited) and operational highlights for its Q3 ended November 30, 2018 . The Company  stated that it has gained considerable ground during this period in keeping with its refined emphasis on strategic key markets and partners capable of facilitating exponential growth.

Parcel volumes for the quarter ended November 30, 2018 increased a significant 16.9 percent more than the equivalent quarter the prior year. Parcel volumes in Q3 FY 2019 increased 27.6 percent from those in Q2 FY 2019. During FY 2018, the change in parcel volumes between Q2 and Q3 comprised a 10.4 percent increase.

PUDO, Inc. (PDPTF), closed Wednesday's trading session at $0.6082, even for the day. The average volume for the last 3 months is 680 and the stock's 52-week low/high is $0.288/$2.09.

chart

DiaMedica Therapeutics, Inc. (DMAC)

Penny Stock Hub, Stockhouse, GuruFocus, Marketwired, Zacks, OTC Markets, Barchart, Business Insider, StreetInsider, MarketWatch, The Street, and WeeklyHub reported previously on DiaMedica Therapeutics, Inc. (DMAC), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

DiaMedica Therapeutics, Inc. concentrates on improving the lives of patients with neurological and kidney diseases associated with low KLK1 levels. The Company is developing innovative treatments where there is significant unmet clinical need or where no current therapies are available with a focus on neurological and kidney diseases. A clinical stage biopharmaceutical company, DiaMedica Therapeutics is headquartered in Minneapolis, Minnesota.

DiaMedica is developing DM199. This is a recombinant (synthetic) human protein for patients suffering from neurological and kidney diseases. DM199 has undergone clinical testing that demonstrates its exceptional safety as a potential treatment for an array of disorders. The Company is positing DM199 for the treatment of diabetic nephropathy and post-insult treatment from acute ischemic stroke (AIS).

DiaMedica Therapeutics is presently conducting a clinical trial designed to identify a dose of DM199 that is comparable to the human urinary and porcine approved versions in Asia. The results of the study will direct dosing for Phase II and Phase III clinical trials.

Furthermore, the Company has identified chronic kidney disease (CKD) caused by Type 1 diabetes as the primary indication for its first kidney disease trial. It announced in February of 2018 the first patient enrollment, at the Royal Melbourne Hospital, Melbourne Australia, in its Phase 2 REMEDY trial assessing the safety, tolerability and markers of therapeutic efficacy of DM199 (recombinant human KLK1) in patients suffering from acute ischemic stroke.

Ahon Pharmaceutical Co Ltd. (Ahon Pharma), a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co. Ltd, (Fosun Pharma) and DiaMedica Therapeutics have entered into a license and collaboration agreement. This agreement allows Ahon Pharma to have exclusive rights to develop and commercialize DM199 for acute ischemic stroke in mainland China, Taiwan, Hong Kong S.A.R. and Macau S.A.R. Fosun Pharma is one of China’s largest pharmaceutical firms.

In January, DiaMedica Therapeutics announced that the U.S. Food and Drug Administration (FDA) accepted the Company’s Investigational New Drug application (IND) for the initiation of a Phase Ib clinical trial of DM199 in patients with moderate or severe Chronic Kidney Disease (CKD) caused by Type I or Type II diabetes. The multi-site clinical study will enroll 32 subjects to assess DM199 safety, tolerability and drug levels (pharmacokinetics) in this specific population. This study will enroll subjects over a 12 day period. Moreover, it will include other end points that include renal biomarkers.

In addition, last month, DiaMedica Therapeutics announced the publication of a paper titled  “Human Tissue Kallikrein In The Treatment Of Acute Ischemic Stroke” in the peer reviewed journal, Therapeutic Advances in Neurological Disorders (TAND). The paper summarizes the mechanistic rationale for using KLK1 to treat patients with acute ischemic stroke (AIS). It summarizes human preclinical and clinical data supporting the hypothesis that KLK1 treatments may improve outcomes after AIS.

Co-author Todd Verdoorn, PhD., Chief Scientific Officer of DiaMedica Therapeutics, said, “DiaMedica is committed to providing helpful information to healthcare professionals and their patients regarding novel, experimental treatment strategies that may improve microvascular circulation and stroke. This paper, which reviews the published information about KLK1 and AIS, further supports the rationale for our ongoing Phase II REMEDY Clinical Trial.”

DiaMedica Therapeutics, Inc. (DMAC), closed Wednesday's trading session at $3.30, up 1.23%, on 15,349 volume with 86 trades. The average volume for the last 3 months is 77,117 and the stock's 52-week low/high is $0.2188/$6.53.

chart

Aurania Resources Ltd. (AUIAF)

Investing News Alerts, StockCharts, Streetwise Reports, Stockwatch, OTC Markets, Penny Stock Hub, Junior Mining Network, Wallet Investor, 4-Traders, MarketWatch, Stockhouse, Barchart, GuruFocus, Morningstar, Investors Hangout, and TradingView reported previously on Aurania Resources Ltd. (AUIAF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Aurania Resources Ltd. is a junior exploration mining company based in Toronto, Ontario. The Company engages in the identification, evaluation, acquisition and exploration of mineral property interests. Its focus is on precious metals and copper. The Company’s flagship asset is The Lost Cities-Cutucu Project. Aurania Resources lists on the OTC Markets’ OTCQB.

The Lost Cities-Cutucu Project is situated in the Jurassic Metallogenic Belt in the eastern foothills of the Andes mountain range of southeastern Ecuador. The Lost City Project is in the southeastern part of the Republic of Ecuador, in the Province of Morona-Santiago. The Project comprises circa 208,000 hectares in 42 concessions occupying the central part of the Cordillera de Cutucu.  The concessions extend roughly 95 km along the Cordillera.

Aurania Resources also has three projects in Canton Valais, Switzerland. These are Siviez (Uranium, Copper and Gold), Marécottes (Uranium), and Mont Chemin (Gold). All of these projects are 100 percent held through Aurania’s wholly-owned subsidiary AuroVallis SARL.

Aurania Resources reported this past November that gold and pathfinder elements typical of epithermal systems were detected in stream sediments from an area about 5 kilometers (km) long in the Tinchi target in its Lost Cities Cutucu project in southeastern Ecuador. The Tinchi target lies along trend of the Kirus region in which high-grade copper has been discovered.

Aurania Resources also reported in November that its exploration teams discovered silver-lead-zinc mineralization in grab samples that run as high as 325 g/t silver, 48 percent zinc, and 39 percent lead, discovered between the new Tiria epithermal gold-silver target and the Jempe copper porphyry zone in its Lost Cities - Cutucu Project.

In January, Aurania Resources reported up to 9 percent copper with 185 grams per tonne (g/t) silver from grab samples of rock in streams draining a doughnut-shaped magnetic feature identified as the "Tsenken-A" porphyry target in magnetic data from the Lost Cities - Cutucu Project.

Dr. Keith Barron, Aurania’s Chairman and Chief Executive Officer, said, "The significance of these high-grade copper results is that they suggest that the highly magnetic feature at Tsenken - rather than being one very large, broad target area - is resolving into a cluster of discrete magnetic features, each of which could be a porphyry body. So, rather than having one potential source of copper at Tsenken, we probably have multiple sources that underscore the mineralization potential of the target area…”

Aurania Resources Ltd. (AUIAF), closed Wednesday's trading session at $2.14, down 0.27%, on 2,930 volume with 7 trades. The average volume for the last 3 months is 3,362 and the stock's 52-week low/high is $1.025/$2.70.

chart

Beyond Commerce, Inc. (BYOC)

Zacks, OTC Markets, Penny Stock Tweets, Stockhouse, InvestorsHub, YCharts, Street Insider, Market Screener, Wallet Investor, Simply Wall St, Financial Content, MarketWatch, Investors Hangout, Barchart, The Street, Tip Ranks, 4-Traders, GuruFocus, Stockopedia, OTC.Watch, TradingView, Morningstar, Insider Financial, and Stockinvest reported earlier on Beyond Commerce, Inc. (BYOC), and we also report on the Company, here at the QualityStocks Daily Newsletter.

Beyond Commerce, Inc. is a planned provider of B2B (Business to Business) internet marketing analytics, technologies, and related services. The Company’s planned objective is to develop, acquire, and deploy disruptive strategic software technology that will build on organic growth potential. Additionally, its planned goal is to exploit cross-selling opportunities. Beyond Commerce is based in Las Vegas, Nevada. The Company’s shares trade on the OTC Markets Group’s OTCQB.

The Company operates as a holding enterprise that focuses on “big data” companies in the global B2B Internet Marketing Analytics/Technology and Services space. Beyond Commerce plans to provide a cohesive digital product and services platform. This is to provide clients with a single point of contact for their big data, marketing and related sales initiatives. The Company’s emphasis is to develop, acquire, and also deploy disruptive strategic software technology and market-changing business models through acquisition or organic growth.

In August of 2018, Beyond Commerce announced that it was added to the LD Micro Index effective August 1, 2018. Beyond Commerce Chairman and Chief Executive Officer, Mr. George Pursglove, said at that time, "This is an exciting time for us as we continue to execute on business milestones which are translating into additional exposure in the capital markets and building on our goals for corporate transparency and credibility with stakeholders. LD Micro has championed the microcap space and I am proud that we have been included in their index and to be recognized with other successful peers in the microcap space."

Yesterday, Beyond Commerce announced that it signed a definitive business combination agreement with PathUX, LLC. Beyond Commerce Chairman and Chief Executive Officer, Mr. George Pursglove, said, "PathUX provides Cloud based marketing automation software and will make a great addition to our future vision, has recurring revenues and a great team. We look forward to our future growth plans together. We expect the provisions of the agreement to be implemented in the second quarter of 2019.”

Beyond Commerce, Inc. (BYOC), closed Wednesday's trading session at $0.05865, down 3.22%, on 1,838,732 volume with 78 trades. The average volume for the last 3 months is 745,878 and the stock's 52-week low/high is $0.00255/$0.159.

chart

BioVie, Inc. (BIVI)

NetworkNewsWire, Penny Stock Tweets, Stockhouse, Investor Place, Wallmine, Wealth Insider Alert, InvestorsHub, Morningstar, YCharts, EuroInvestor, MarketWatch, GuruFocus, Street Insider, and Simply Wall St reported earlier on BioVie, Inc. (BIVI), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

BioVie, Inc. focuses on the discovery, development, and commercialization of unique drug therapies for liver disease. At present,  the clinical-stage Company is centering on commercializing BIV201. This is a novel approach to the treatment of ascites due to chronic liver cirrhosis. OTCQB-listed, BioVie has its corporate headquarters in Beverly, Massachusetts.

The Company states that BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, NASH, and alcoholism. The US Patent and Trademark Office (USPTO) issued US Patent No. 9,655,945 covering BioVie’s new drug candidate BIV201.   

BIV201 has Orphan Drug designation for the most common of these complications, ascites, which represents a major unmet medical need. The Food and Drug Administration (FDA) has never approved any drug specifically for treating ascites.

BIV201 is a continuous infusion of the peptide terlipressin, first undergoing development for the treatment of refractory ascites. Terlipressin, dosed differently, is approved in about 40 nations for other complications of liver cirrhosis coming up from a similar disease pathway. Terlipressin is not available in the United States. 

BioVie announced in April 2017 that it received notice from the FDA that the planned Phase 2a clinical trial of its new drug candidate BIV201 could begin. This was based on BioVie’s IND to conduct a study in patients with refractory or intractable ascites due to advanced liver cirrhosis. BioVie also announced in April 2017 the signing of a Cooperative Research and Development Agreement (CRADA). This is to conduct a Phase 2a clinical trial of BIV201 in patients with refractory or intractable ascites because of advanced liver cirrhosis. 

The FDA has granted Fast Track designation for BIV201 (continuous infusion terlipressin), BioVie’s patented Orphan drug candidate. BIV201 is currently undergoing evaluation for the treatment of refractory ascites because of liver cirrhosis in a mid-stage (Phase 2a) U.S. clinical trial.

The FDA has granted Orphan Drug designation to BioVie for terlipressin for the treatment of hepatorenal syndrome (HRS). BioVie earlier secured an Orphan Drug designation for terlipressin for treating ascites. The Company is exploring additional Orphan designation opportunities.

This month, BioVie announced that it completed enrollment in a Phase 2a open-label clinical study of BIV201 (continuous infusion terlipressin) in patients with refractory ascites because of advanced liver cirrhosis.

Patrick Yeramian, MD, BioVie’s Chief Medical Officer, said, “We are pleased to have achieved this important clinical milestone as we continue to develop BIV201 for patients with refractory ascites who are at high risk of deadly complications. What we have learned from this initial study is informing our next clinical trial design. The results will be presented to the FDA in the first half of 2019 and we expect to receive guidance on the BIV201 clinical development plan.”

BioVie, Inc. (BIVI), closed Wednesday's trading session at $0.03, down 25.00%, on 28,500 volume with 4 trades. The average volume for the last 3 months is 44,881 and the stock's 52-week low/high is $0.012/$0.25.

chart

OWC Pharmaceutical Research Corp. (OWCP)

Tip Ranks, InvestorsHub, MarketWatch, PR Newswire, Insider Financial, The Street, Stock Invest, OTC Markets, Promotion Stock Secrets, Street Register, The Profit Buzz, CFN Media Group, Seeking Alpha, Stockhouse, Morningstar, and Cannabis Financial Network News reported previously on OWC Pharmaceutical Research Corp. (OWCP), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

OWC Pharmaceutical Research Corp. engages in the research and development (R&D) of cannabis-based medical products. The Company provides medical products for the treatment of different medical conditions and/or diseases. These include multiple myeloma, psoriasis, PTSD, migraines, and delivery systems. OTCQB-listed, OWC Pharmaceutical Research is headquartered in Petach Tikva, Israel. One World Cannabis Ltd. is a wholly-owned subsidiary of OWC Pharmaceutical Research.

OWC has entered into research and collaboration agreements with three of the leading research institutions in Israel. These include Sheba Academic Medical Center, one of the top academic hospitals in the Middle East. These agreements serve as the basis for the Company’s clinical trials. They ensure that all of its studies have been, and will continue to be, founded on established research protocols of the U.S. Food and Drug Administration (FDA), Institutional Review Boards, and Independent Ethical Committees.

OWC has completed the development of a proprietary, cannabinoid-enriched sublingual tablet for the administration of medical cannabis. The technology behind the tablet is protected. It provides for the ingestion of almost any dosage of medical cannabis with a sublingual delivery mechanism, where the compounds are absorbed directly into the patient's blood by way of oral epithelial tissue.

Subsidiary One World Cannabis’ Research Division centers on pursuing clinical trials evaluating the effectiveness of cannabinoids in the treatment of diverse medical conditions. Its Consulting Division’s dedication is to helping governments and companies navigate complex international cannabis regulatory frameworks. 

OWC has received the first ever Institutional Review Board (IRB) approval to conduct a safety study for a cannabis-based topical cream with more than 3 percent THC. The Company is conducting a safety study (FDA Phase 1 equivalent) in one of the largest academic hospitals in Israel.

Going forward, OWC Pharmaceutical Research’s comparative safety and efficacy trial for its tablet will be initiated in Q2 of 2019. The expectation is that the duration of this trial will be four months. Additionally, the efficacy trial for the Company’s cannabis cream will be initiated in Q3 of 2019. The duration of this trial is expected to be about 24 months.

Regarding its Multiple Myeloma (cancer therapy) program, OWC successfully completed a dosing study for its proprietary, systemic emulsion delivery system in rats. The Company’s pre-clinical results indicated strong potential of its cannabis-based formulations to kill cancer cell lines and tumors in mice. OWC stated that this important milestone was fundamental to enable the translation of these pre-clinical results into a potential therapy.

OWC Pharmaceutical Research Corp. (OWCP), closed Wednesday's trading session at $0.0561, up 13.39%, on 1,704,738 volume with 195 trades. The average volume for the last 3 months is 848,637 and the stock's 52-week low/high is $0.044/$0.498.

chart

SOL Global Investments Corp. (SOLCF)

InvestorIntel, Stockwatch, Investors Hangout, Morningstar, TradingView, Investing News, The Cannabis Investor, Wallstreet Online, InvestorsHub, GuruFocus, Interactive Brokers, Barchart, Marketbeat, and Market Screener reported earlier on SOL Global Investments Corp. (SOLCF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

SOL Global Investments Corp. is an international cannabis company. Its focus is on, but not limited to, cannabis and cannabis related companies in legal U.S. States. The Company’s investment emphasis is U.S. Cultivation, U.S. Dispensaries, Research and Development (R&D), and International Assets. The Company formerly went by the name Scythian Biosciences Corp. SOL has offices in Toronto, Ontario; Fort Lauderdale, Florida, and London, United Kingdom (UK). The Company lists on the OTC Markets Group’s OTCQB.

SOL Global Investments’ strategic investments and partnerships across cultivation, distribution and retail complement its R&D program with the University of Miami. The Company has partnered with the University of Miami and its neuroscientific team to conduct pre-clinical and clinical trials of the impact of CBD on sport concussions.

Recently, SOL Global Investments announced an investment in, and strategic partnership with, European medical cannabis company, GreenLight Pharmaceuticals Ltd. Under the terms of this transaction, SOL Global Investments will acquire a 25 percent stake in the equity of GreenLight for €1.8 million. SOL has an option to increase its stake to 51 percent.

SOL Global has also acquired an option to acquire a 75 percent stake in a future GreenLight subsidiary that successfully obtains a cannabis cultivation license in Ireland or Northern Ireland for an aggregate exercise price of roughly €1 million. GreenLight Pharmaceuticals of Dublin, Ireland, is a vertically-integrated medical cannabis company with a clinical research and development operation (led by Dr. James Linden), a seed genetics program, cultivation operations, and CBD brand and distribution operations.

GreenLight's distribution operations include its proprietary 'GreenLight Food Supplements' subsidiary and other plant extract-based products now in development. GreenLight’s food supplements operations provide products in Ireland and the UK, with development underway in Spain, France, Russia, Poland, and the U.S. GreenLight Pharmaceuticals presently holds distribution agreements with 1,000 pharmacies throughout Ireland and the UK.

SOL Global Investments Corp. (SOLCF), closed Wednesday's trading session at $2.55, up 5.81%, on 42,502 volume with 44 trades. The average volume for the last 3 months is 73,013 and the stock's 52-week low/high is $0.768/$23.385.

chart

NioCorp Developments Ltd. (NIOBF)

Savvy Trader Resource, InvestorsHub, Stockhouse, StreetInsider, Morningstar, Proactive Investors, Equity Clock, MarketWatch, 4-Traders, InvestorIntel, Junior Mining Network, and Simply Wall St reported on NioCorp Developments Ltd. (NIOBF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

NioCorp Developments Ltd. is a developer of superalloy metals and is developing a superalloy materials project in Southeast Nebraska. The Project will produce Niobium, Scandium, and Titanium. The Company formerly went by the name Quantum Rare Earth Developments Corp. It changed its corporate name to NioCorp Developments Ltd. in March 2013. OTCQX-listed, NioCorp is headquartered in Centennial, Colorado.

Niobium is used to produce superalloys and high strength, low alloy steel. Scandium is a superalloy material that can be combined with aluminum to make alloys with increased strength and improved corrosion resistance. Titanium is used in varied superalloys.

NioCorp Developments is developing North America's only niobium/scandium/ titanium project. The Elk Creek Project is the highest-grade niobium project in North America, and the largest prospective producer of scandium worldwide. The Elk Creek Project is positioned near Elk Creek, Nebraska.

The Elk Creek Feasibility Study (FS) shows anticipated production of 7,055 tonnes per annum (tpa) of Ferroniobium, 103 tpa of Scandium Trioxide, and 11,445 tpa of Titanium Dioxide over its 32-year operating life.

The estimation is that the Elk Creek Project will have pre-tax Net Present Value (NPV) of US$2.3 billion, with a pre-tax Internal Rate of Return (IRR) of 24.3 percent, and to produce gross Life Of Mine (LOM) Revenue of $17.6 billion, with Operating Margin of $12.2 billion. The economics were calculated using an 8 percent discount rate.

In July, NioCorp noted that a U.S. Senate Committee chose to highlight NioCorp Developments’ Elk Creek Critical Minerals Project due to the uniqueness of the critical minerals it plans to make and because of the Project’s success in lessening its expected environmental impacts.

NioCorp testified in July in Washington, D.C. at a hearing of the U.S. Senate Energy and Natural Resources Committee.  The hearing examined the topic of “critical minerals” and opportunities to strengthen U.S. mineral security.

Mr. Mark A. Smith, NioCorp Developments’ Chief Executive Officer and Executive Chair of NioCorp, said he was pleased that the Company was selected from among hundreds of companies and projects to testify at the hearing.

Mr. Smith said, “We are very gratified that the Energy and Natural Resources Committee chose to highlight the Elk Creek, Nebraska Critical Minerals Project. The Committee had hundreds of options from which to choose in terms of which companies and projects to highlight at a hearing like this.  I believe they chose NioCorp and the Elk Creek Project because of the many highly unique aspects of this project, including the multiple critical minerals we will produce, the fact that we will produce only critical minerals, and because the many environmental advances the Project has been able to achieve.”

NioCorp Developments Ltd. (NIOBF), closed Wednesday's trading session at $0.475538, up 1.18%, on 33,590 volume with 17 trades. The average volume for the last 3 months is 82,429 and the stock's 52-week low/high is $0.385/$0.602.

chart

Zynex, Inc. (ZYXI)

SmallCapVoice, SmarTrend Newsletters, FeedBlitz, Zacks, BUYINS.NET, FNNO Newsletters, Daily Markets, and TaglichBrothers reported earlier on Zynex, Inc. (ZYXI), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Zynex, Inc. is a medical technology company listed on the OTCQB. It specializes in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation,  neuro diagnostics, cardiac and blood volume monitoring.  In addition, the Company is developing a new blood volume monitor (non-invasive Blood Volume Monitor, CM-1500) for use in hospitals and surgery centers.  Established in 1996,  Zynex  has its head office in Englewood, Colorado. 

The Company’s product lines are completely developed, Food and Drug Administration (FDA)-cleared, and commercially sold internationally. Zynex engineers, manufactures, markets, and sells its own design of medical devices in three subsidiaries. 

Zynex Medical is a provider of electrotherapy products for home use. Zynex Monitoring Solutions develops products for cardiac monitoring for use in hospitals. Zynex NeuroDiagnostics develops devices for EMG and EEG diagnostic purposes in the neurology clinic markets.   

Zynex markets and sells its own design of electrotherapy medical devices used for pain management and rehabilitation. It also markets and sells its proprietary NeuroMove device designed to help recovery of stroke and spinal cord injury patients. 

Zynex  believes that its non-invasive Blood Volume Monitor, CM-1500, will be the first device to provide an indication of fluid balance and blood loss in the operating room or potential post-surgical internal bleeding in recovery.

New products Zynex has added include JetStream Hot/Cold Therapy, Aspen LSO Backbracing and Comfortrac cervical traction. All of these products are targeted at treating acute and chronic pain without side-effects. 

Last month, Zynex announced the introduction of the NeuroMove device into the Company’s expanding direct sales force in the United States market. The design of the NeuroMove™ device is to aid stroke survivors in regaining movement using the brain's ability to rewire itself, also known as "neuro-plasticity".

Mr. Thomas Sandgaard, Founder and Chief Executive Officer, said, "I am excited to announce that we are re-launching the NeuroMove 900 stroke and traumatic brain injury rehabilitation product to our sales force over the next couple of months.  We have for many years sold the NeuroMove device primarily to rehabilitation clinics in the US as well as internationally and while the device is designed with home use in mind we have not previously promoted it through our direct sales force. The NeuroMove 900 is a complimentary product for a large portion of our direct sales force aimed at the rehabilitation market.

At the end of February, Zynex reported financial results for its Q4 ended December 31, 2017. Revenue increased 178 percent year over year to $8.1 million. Net Income of $3.3 million grew 1,482 percent year over year.

Moreover, Adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of $3.9 million grew 481 percent year over year. Zynex produced $8.3 million of Cash from Operations during 2017. This represents an increase of 367 percent versus $1.8 million in 2016. As of December 31, 2017, Zynex had Working Capital of $4.4 million versus a deficit of $4.3 million at December 31, 2016.

Zynex, Inc. (ZYXI), closed Wednesday's trading session at $4.8628, up 1.63%, on 29,976 volume with 85 trades. The average volume for the last 3 months is 22,796 and the stock's 52-week low/high is $2.40/$5.43.

chart

Patriot Gold Corp. (PGOL)

OtcWizard, Gold Investment Letter, Real Pennies, and Standout Stocks reported previously on Patriot Gold Corp. (PGOL),  and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Patriot Gold Corp. is a precious metals exploration and production company. Its mission is to discover and develop significant gold and silver assets in the States of Arizona and Nevada. At present, the Company holds a portfolio of four projects. These are the Moss project in Arizona and three in Nevada (Bruner, Vernal, and Windy Peak). Patriot Gold has its corporate office in Las Vegas, Nevada.

The Company holds a 3 percent royalty in the Moss Mine in Arizona, an interest in the Bruner gold project in Nevada, and a 100 percent interest in the Vernal and Windy Peak projects in Nevada. 

  The Moss Mine Project is within the historic Oatman District, 10 miles east of Bullhead City, Arizona and around 70 miles southeast of Las Vegas. The Moss Mine is owned by Northern Vertex Mining Corp.

The Bruner gold project property is roughly 130 miles east-southeast of Reno, Nevada. It is at the northern end of the Paradise Range and 45 miles northwest of the Round Mountain Mine. Patriot Gold owns a 2 percent royalty in the Bruner gold project. The Bruner gold project is owned by Canamex Resources Corp.

The Windy Peak Gold Project consists of 79 unpatented mineral claims in the Fairview mining district in southwest Nevada. Windy Peak is easily accessed. It is approximately 45 miles southeast of Fallon and 6 miles from Middlegate.

The Vernal gold project is in its early stage. The property is approximately 140 miles east-southeast of Reno, Nevada, on the west side of the Shoshone Mountains. The property consists of 12 unpatented mining claims (240 acres).

The Bruner and Vernal gold projects are in Nevada's Walker Lane, which hosts numerous major deposits. These include the Goldfield (greater than 5 million ounces of post production and present reserves) and the Comstock (greater than 8 million ounces).

Last month, Patriot Gold reported that the Moss Mine, owned by Northern Vertex Mining, is quickly advancing toward the pouring of its initial commercial gold/silver dore bars, according to a recent announcement by Northern Vertex. Northern Vertex Mining announced that around 7,800 tons of ore were stacked on the pad so far.

Northern Vertex is moving towards an initial stacking rate of 2,500 tpd, and subsequently to 5,000 tpd. Additionally, it reported that all of the crushing plant components were tested and commissioned, piping on the heap leach pad started, and the refinery furnace was to be commissioned.

In addition, in February, Patriot Gold announced that permitting is in place for its 2018 drilling program on its Windy Peak gold project in Nevada. The Company has identified a number of drilling targets. Patriot is in the process of choosing a drilling contractor.

Patriot Gold Corp. (PGOL), closed Wednesday's trading session at $0.0636, up 0.79%, on 1,200 volume with 1 trade. The average volume for the last 3 months is 28,633 and the stock's 52-week low/high is $0.0438/$0.1469.

chart

LexaGene Holdings, Inc. (LXXGF)

MarketWatch, Stockhouse, Capital Cube, Barchart, Pinnacle Digest, Stockwatch, YCharts, MetalsNews.com, The Street, OTC Markets, Dividend Investor, Insider Financial, Investor Place, Financial Trends, and Markets Insider reported on LexaGene Holdings, Inc. (LXXGF), and today we choose to report on the Company as well, here at the QualityStocks Daily Newsletter.

A biotechnology company listed on the OTCQB, LexaGene Holdings, Inc. develops instrumentation for pathogen detection. It is developing the LX6, which is the very first fully automated pathogen detection platform that is open-access.  This open-access feature will enable end-users to target any pathogen of interest, as they can load their own real-time PCR assays onto the instrument for customized pathogen detection. LexaGene Holdings has its corporate headquarters in Beverly, Massachusetts.

Earlier this month, LexaGene announced that it considerably expanded its operations in Massachusetts. The Company recently signed a lease for a 17,500-square-foot space, located at 500 Cummings Center, Suite 4550, in Beverly.

LexaGene Holdings is working to change the pathogen detection landscape through providing a customizable sample-to-answer instrument, which is more rapid and sensitive than anything presently available. It is working to transform the way pathogen testing is performed by multi-billion dollar industries. These industries include food safety, veterinary diagnostics, water quality management, aquaculture farming, and more.

LexaGene Holdings has strategic relationships with Boston Engineering – a development partner; as well as the Lawrence Livermore National Laboratory. The Company’s Microfluidic Technology is open access - users can load standard pathogen specific assays onto the instrument for customized testing.

A feature of this technology is extreme sensitivity. The flow-through instrument processes huge sample volumes to maximize the chances of detecting ultra-rare pathogens. The Microfluidic Technology features low cost per test and it is also user-friendly.

At the end of November 2017, LexaGene announced that it completed the assembly of its prototype for what will be the world’s first fully automated, open-access and on-site pathogen detection platform. This technology will be able to screen for up to 22 pathogens at once and deliver results in one hour. The design of the technology is also to be used by people with no knowledge of automated instrumentation, microbiology, or molecular biology.

Yesterday, LexaGene Holdings announced that the TSX Venture Exchange ranked the Company in its 2018 TSX Venture 50. This is a yearly ranking of top performing companies on the Exchange.

Dr. Jack Regan, LexaGene Holdings’ Chief Executive Officer, said, “Being recognized as a top 50 company for the Exchange reflects the rapid growth we’ve experienced in 2017 and great support from the investment community. Following our recent completion of the assembly of our prototype for what will be the world’s first fully automated, open-access and on-site pathogen detection platform, LexaGene is poised to make a powerful impact for industries interested in pathogen detection – from food safety to veterinary diagnostics.”

LexaGene Holdings, Inc. (LXXGF), closed Wednesday's trading session at $0.6087, up 2.30%, on 339,259 volume with 40 trades. The average volume for the last 3 months is 41,375 and the stock's 52-week low/high is $0.349/$1.159.

chart

eWellness Healthcare Corp. (EWLL)

StockHideout and Penny Stock Prodigy reported previously on eWellness Healthcare Corp. (EWLL), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Listed on the OTCQB, eWellness Healthcare Corp. develops a telemedicine platform. This platform is for providing Distance Monitored Physical Therapy programs. These programs are for pre-diabetic, cardiac, and health challenged patients through contracted physician practices and healthcare systems. eWellness Healthcare is headquartered in Culver City, California.

The Company has launched PHZIO. The design of this Physical Therapy Telemedicine platform is to extend and scale a physician’s practice. eWellness Healthcare is the first physical therapy telemedicine company to provide insurance reimbursable real-time distance monitored treatments.  

eWellness Healthcare’s business model is to license the PHZIO platform to any Physical Therapy (PT) clinic in the U.S. and/or have large-scale employers use its PHZIO platform as a completely PT monitored corporate wellness program. eWellness Healthcare’s PHZIO extends a traditional practice online. 

The main features of the PHZIO platform include video treatment protocols, real-time patient monitoring, patient induction forms, a patient video journal, and post treatment evaluations. Furthermore, main features include integrated billing, patient metrics, as well as user administration & customization. 

PHZIO also scales a practice’s billable rates. In addition, it provides tools to make growing a business easier.

Regarding the Patient Dashboard, the PHZIO Dashboard enables clients to login securely to access prescribed treatment protocols. PHZIO is user-friendly and highly reliable to operate for PT and Patient. It is also a complete on-line PT telemedicine intervention system. 

Evolution Physical Therapy has added eWellness Healthcare's Telehealth PT Services at its four clinical locations in Los Angeles, California. This includes Culver City, Playa Vista, Beverly Hills, and Brentwood. Mr. Darwin Fogt, Chief Executive Officer of eWellness Healthcare, owns Evolution Physical Therapy.

This past October, eWellness Healthcare announced the launch of its new patient lead generation platform, LeadRemedy.com. Lead Remedy increases a Practices’ social networks reach through tapping in to the employees of the practice and their social circles.

Each week, relevant physical therapy content is sent to practice employees to review and share. Upon a prospective patient viewing the content, the Practice’s brand is always present; the patient can book an evaluation appointment directly from the viewing page.

Mr. Darwin Fogt, eWellness Healthcare Chief Executive Officer, stated, “Physical Therapy Clinics are continually seeking to attract new patients in order to grow and maintain the success of their Practices. Traditionally, this is done through doctor referrals, word of mouth or advertising.  Few practices use social media content to attract new patients. Typically, this lack of social media presence is due to the Practice Owners not having the capacity or capability to produce the content needed to be relevant to prospective patients. Practices that sign up for our Lead Remedy Service solve this outreach problem”.

eWellness Healthcare Corp. (EWLL), closed Wednesday's trading session at $0.11975, up 3.23%, on 69,555 volume with 14 trades. The average volume for the last 3 months is 540,984 and the stock's 52-week low/high is $0.045/$0.339.

chart

Agritek Holdings, Inc. (AGTK)

CFN Media Group, Promotion Stock Secrets, PennyPro, SmallCapVoice, and Cannabis Financial Network News reported on Agritek Holdings, Inc. (AGTK), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Formed in 2010, Agritek Holdings, Inc. is a fully integrated, active cannabis real estate investor and branding consultant in the legal cannabis sector. The Company provides innovative technology and agricultural solutions for the medicinal and recreational cannabis industry. Currently, Agritek owns property in Colorado approved for cultivation, and manufacturing capabilities through California partnerships. It also owns a number of Hemp and cannabis brands for distribution including "Hemp Pops" and "California Premiums". Agritek Holdings is headquartered in Miami, Florida. The Company has a satellite office in San Juan, Puerto Rico

Agritek does not directly grow, harvest, or distribute or sell cannabis or any substances that violate or contravene United States law or the Controlled Substances Act. It does not intend to do so in the future. The Company’s solution is an integrated platform designed for commercialization in three high-value segments of the global cannabis market – Real Estate, AGTK Brands/IP, and Infrastructure.

Agritek’s Colorado property is 80-Acres approved for cannabis cultivation or manufacturing facility in Pueblo, Colorado. Its Puerto Rico property is a 25,000-sq. ft. licensed cannabis cultivation and manufacturing facility. Agritek’s Canada property is a cannabis friendly "Bud & Breakfast" concept. It is one 1-hour from Quebec City. It is on 15-acres that includes nine guest rooms plus a separate detached grow facility.

Agritek’s brands are a premium positioned set of consumer brands for medical wellness and recreational use. Agritek owns a number of hemp and cannabis brands for distribution. These include MD Vapes, MicroDose Strips, and the above-mentioned "Hemp Pops" and "California Premiums."

Agritek Holdings announced this past April that it completed, and fully executed, a five-year operational and exclusive licensing agreement with a 25,000-sq. ft. and one of the largest approved cultivation facilities in San Juan, Puerto Rico. The Company will be the exclusive funding source, and supervise all infrastructure buildout, equipment lease/finance, security systems and personnel and provide access of experienced Colorado and California cultivation crews to ensure the facility meets all standard operating procedures as set forth by the Department of Health of Puerto Rico.

With the five-year operational contract and licensing agreement, Agritek will receive revenue in the form of property rent, licensing fees on all vaporizer and edible brands, equipment and lighting rental and financing fees along with equity interest in the property.

Also, in May, Agritek Holdings announced that it executed a land purchase agreement to purchase a "420 Style" resort and estate property about one hour outside of Quebec City, Quebec. This 15-acre estate comprises nine innovative guest suites and horse stables. It is within walking distance to a public golf course that the Company will have ownership in for guests staying at the resort. A separate structure will serve as a small grow facility run by patient employees and caretakers on the property that may be toured by guests of the facility.

This month, Agritek Holdings announced that Phase One of construction is commencing this month at the 1919 Clinic's 25,000 square foot cultivation and manufacturing facility located in San Juan, Puerto Rico. Agritek will provide funding for the build out of the operation, extraction and all equipment, and cultivation experts under the Agritek team via its executed five-year Operations and Licensing Agreement with 1919 Clinic.

Last week, Agritek Holdings announced its initial orders from its' state licensed manufacturer for its brand "MicroDose" Oral Strips or "MD Strips" for the medicinal market of California. First orders and samples are being sent to dispensaries and local delivery services in San Diego and Orange County this month. Agritek will provide the licensing and packaging to produce the exclusive line of 10 mg and 50 mg oral strips as a medicinal alternative for patients.

Agritek Holdings, Inc. (AGTK), closed Wednesday's trading session at $0.00348, up 8.75%, on 3,575,778 volume with 73 trades. The average volume for the last 3 months is 18,932,001 and the stock's 52-week low/high is $0.0017/$0.0245.

chart

Midwest Energy Emissions Corp. (MEEC)

MissionIR, Wall Street Resources, NBT Equities Research, Marketbeat.com, TopPennyStockMovers, Greenbackers, SeriousTraders, and PennyStocks24 reported on Midwest Energy Emissions Corp. (MEEC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Midwest Energy Emissions Corp. is an emerging leader in mercury emissions control technology for the international coal-power industry. The Company develops and utilizes patented and proprietary technologies to remove mercury from coal-power plant emissions. Midwest Energy Emissions focuses on the delivery of mercury capture technologies to power plants and other industrial coal-burning units in North America, Europe, and Asia. The Company has its headquarters in Lewis Center, Ohio.

Midwest Energy Emissions employs patented technology, which has been shown to realize mercury removal levels compliant with the U.S. Environmental Protection Agency's (EPA) Mercury and Air Toxic Standards (MATS) rule, at a significantly lower cost and with less operational impact than methods now used. This is while preserving the ability for customers to recycle and sell fly-ash for beneficial use.

The Company’s proprietary SEA™ (Sorbent Enhancement Additive) technology delivers a flexible, tunable solution. It permits the worldwide coal-power industry to easily comply with new, highly restrictive regulations on mercury air emissions. The SEA™ approach to mercury capture is precisely tailored for each application to complement a customer’s fuel type and boiler configuration for best results.

Midwest Energy Emissions is adding a new product to its proven, cost-effective mercury capture program, which will reduce mercury emissions by preventing scrubber reemission events. The design of the product is specifically for coal-fired power utilities with wet scrubbers to help remove mercury, and other metals from the scrubber.

Recently, Midwest Energy Emissions acquired all patent rights for its Sorbent Enhancement Additive (SEATM) mercury emissions control technology from the Energy & Environmental Research Center Foundation (EERCF of Grand Forks, North Dakota). It acquired the rights for the price of $2.5 million and 925,000 shares of common stock in Midwest Energy Emissions. EERCF is an organization that works to provide inventive solutions to the globe’s energy and environmental challenges.

Midwest Energy Emissions will host a conference call on Monday, August 14, 2017 at 5:00 p.m. Eastern Time (ET) to discuss its financial results for Q2 ended June 30, 2017.

Midwest Energy Emissions Corp. (MEEC), closed Wednesday's trading session at $0.255, even for the day, on 29,260 volume with 11 trades. The average volume for the last 3 months is 37,791 and the stock's 52-week low/high is $0.11625/$0.469.

chart

The QualityStocks Company Corner

Youngevity International, Inc. (NASDAQ: YGYI)

The QualityStocks Daily Newsletter would like to spotlight Youngevity International, Inc. (YGYI).

Youngevity International, Inc. (NASDAQ: YGYI), a leading omni-direct lifestyle company, announced today that it has entered into a binding agreement to purchase all the assets of Khrysos Global–a Tampa, Florida based manufacturer of hemp-based CBD extraction equipment.

Youngevity International, Inc. (NASDAQ: YGYI) is a leading omni-direct lifestyle company offering a hybrid of the direct selling business model that includes e-commerce and the power of social selling. Among the Top 100 Global Direct Selling Companies, Youngevity offers products from the six top selling retail categories: health/nutrition, home/family, food/beverage (including coffee), spa/beauty, apparel/jewelry, and a range of innovative services. Created through the 2011 merger of Youngevity Essential Life Sciences with Javalution® Coffee Company, today’s Youngevity International Inc. is a virtual worldwide Main Street of products and services under one corporate entity that supports a healthy and empowered lifestyle.

Youngevity International is dedicated to improving lifestyles through the universal desires of vibrant health and flourishing economics. Catering to health-conscious consumers, Youngevity believes that combining the best of the direct selling industry with the fundamentals and capabilities of a traditional business model will maximize shareholder value. The company’s Nutritional, Lifestyle and Telecommunications products and services are distributed through a global network of Preferred Customers and Distributors.

Youngevity’s wholly owned CLR Roasters LLC business line offers quality branded and private label coffee to retail stores, office coffee services, hospitality, food services, distributors, convenience, petrol stores and vending businesses. Today, CLR Roasters is the largest coffee provider for cruise lines in North America and the second largest roaster in the state of Florida. Producing a consistent premium product with superior taste, CLR Roasters has earned numerous certifications that demonstrate the company’s commitment to the craft of providing the highest quality coffee products using the best practice standards available.

Youngevity, operating in the direct-selling channel, is rapidly expanding its product and distributor base through acquisitions and mergers under an innovative concept called “the Network Cloud” that provides other direct selling companies with a home base. The company’s YoungevityGO2 mobile distributor app, a new technology-driven web platform supporting expansion of global e-commerce and social selling platforms, is available on Google Play and the App Store. In addition to the Network Cloud concept, Youngevity International owns CLR Coffee Roasters which operates a traditional coffee roasting business offering a JavaFit® gourmet product line that vertically integrates with Youngevity and its growing network of direct marketers.

Youngevity International offers more than 1,000 high quality, technologically advanced products under the following categories:

  • Health and Nutrition
  • Home and Family
  • Food and Beverage
  • Spa and Beauty
  • Fashion
  • Essential Oils
  • Photo and scrapbooking
  • Services for Home and Business

Youngevity International Inc. has compiled a best-in-class management team with a strong track record of success in private and public companies. Steve Wallach, CEO, has nearly two decades of sales and network marketing experience and has successfully guided Youngevity International Inc. to become an international, publicly-traded direct marketing company positioned for worldwide growth. Dave Briskie, president and CFO, has shepherded the company’s development into a fully vertical coffee roasting and distribution company that owns the direct marketing brand JavaFit® and the retail brand, Café La Rica.

Youngevity has also attracted a stunning group of Brand Evangelists who endorse its products. Among these are actress, author and well-known health and wellness activist Marilu Henner; former NBA basket player, Mike “Stinger” Glenn; former NFL wide receiver Drew Pearson; “Greatest Natural Bodybuilder in the World” Gene Nelson; and WNBA champion, Olympic gold medalist Delisha Jones.

Youngevity International, Inc. (NASDAQ: YGYI), closed the day's trading session at $8.06, up 10.87%, on 2,572,168 volume with 14,030 trades. The average volume for the last 3 months is 160,285 and the stock's 52-week low/high is $3.167/$16.25.

Recent News

chart

Canopy Rivers Inc. (TSX.V: RIV) (OTC: CNPOF)

The QualityStocks Daily Newsletter would like to spotlight Canopy Rivers Inc. (RIV) (CNPOF).

Canopy Rivers Inc. (TSX.V: RIV) (OTC: CNPOF) will report its third quarter fiscal 2019 financial results after markets close on Wednesday February 27, 2019. The Company’s unaudited condensed interim financial statements and Management’s Discussion and Analysis for the three and nine months ended December 31, 2018 will be available on the Company’s profile on SEDAR at www.sedar.com and in the Investors section of the Company’s website at www.canopyrivers.com.

Canopy Rivers Inc. (TSX.V: RIV) (OTC: CNPOF) is the venture capital investment platform of Canopy Growth Corporation (TSX:WEED, NYSE:CGC).

Canopy Rivers is a unique investment and operating platform structured to pursue investment opportunities in the emerging global cannabis sector. Canopy Rivers collaborates with Canopy Growth to identify strategic counterparties seeking financial and/or operating support. Headquartered in Toronto, Canada, Canopy Rivers has developed an ecosystem of complementary cannabis operating companies operating throughout the cannabis value chain.

Canopy Rivers, in collaboration with Canopy Growth, has established a diverse portfolio of cannabis industry investments that includes domestic and international companies, licensed producers, late-stage licensed producer applicants, pharmaceutical formulators, brand developers and distributors, retail networks, and technology and media platforms. Investments are customized for each counterparty and include a balanced mix of equity, debt, royalty and profit-sharing agreements.

Canopy Rivers’ expanding portfolio includes:

  • Agripharm Corp. (private) is an ACMPR licensed producer, acquired by Canopy Growth in January 2017. In November 2017 Agripharm completed a joint venture with globally recognized partners Green House Seeds and Organa Brands. Canopy Growth has sublicensed proprietary technology, trademarks, genetics, know-how and other intellectual property from Agripharm to distribute the suite of Green House and Organa Brands products across the country, when permissible.
  • CanapaR Corp. (private) owns 80% of CanapaR Italy, a Sicily-based company focused on developing and commercializing Italy’s local hemp cultivation industry through its partnership with the renowned Department of Agriculture at the University of Catania and its rapidly building extraction capabilities for the production of organic CBD oil. CanapaR Italy’s outsource farming model with local Sicilian farmers and its university partnership will provide it with a low-cost source of organic CBD oil, which is increasingly used as an input into new commercial products in the growing health and wellness industries.
  • Civilized Worldwide Inc. (private), is a media and lifestyle brand with offices in New Brunswick and California that embraces and highlights modern cannabis culture. Civilized aims to engage the millions of productive, motivated people who choose to enjoy cannabis responsibly as part of their lifestyle. Reaching 2+ million unique visitors per month, North America-wide, Civilized produces engaging content for and about people who enjoy cannabis responsibly.
  • James E. Wagner Cultivation Ltd. (TSXV:JWCA) was founded in 2007 by third generation agricultural and cannabis cultivators. JWC is the first entirely aeroponic producer of cannabis in Canada, and its patent-pending aeroponic production technology, called GrowthStormTM, allows for perpetual harvesting and improved yields. The company was issued a license to cultivate from Health Canada in January 2017 and a subsequent sales license in March 2018.
  • LiveWell Foods Canada Inc. (TSXV:LVWL) was established in 1993 as a nutritional lifestyle company, and operates in the production of fresh produce and food technology. The company’s O-Hemp division distributes bulk and retail hemp products through its existing channel partners. LiveWell entered into a strategic agreement with Canopy Rivers and Canopy Growth in April 2018.
  • PharmHouse (private) is a joint venture between Canopy Rivers and the principals and operators of leading North American greenhouse produce companies. PharmHouse has arranged to acquire a newly built 1.3-million-square-foot greenhouse located in Leamington, Ontario.
  • Radicle Cannabis Inc. (private) is an ACMPR-licensed cannabis company based in Hamilton, Ontario backed by a management team that brings extensive experience in regulated industries, retail distribution, tobacco and pharmaceutical development, as well as Award-winning cannabis horticulturist breeders and medical professionals.
  • Solo Growth (TSXV:ALZ) is a new cannabis retail concept that will operate locations under the name “YSS by Solo,” relying on the expertise of a management team comprised of founding shareholders, senior officers and board members of Solo Liquor Stores Ltd., a leading Canadian liquor retailer. Solo Growth was established through a recapitalization of Aldershot Resources Ltd.’s corporate structure that will allow the company to execute a new retail-focused cannabis business strategy.
  • Spot Therapeutics Inc. (private) is an applicant that was acquired by Canopy Growth in August 2017 to solidify its Maritimes expansion strategy and less than four weeks later Canopy Growth signed a supply MOU with the New Brunswick government. Canopy Rivers purchased the property and entered into a long-term lease and committed funding agreement with Canopy Growth.
  • TerrAscend Corp. (CSE:TER) cultivates high-quality cannabis in an indoor hydroponic facility, backed by a strategic investor boasting a strong background in the pharmaceutical space and an extensive portfolio of specialty pharma assets.
  • Vert Mirabel (private) is a joint venture that was established in December 2017 between Canopy Rivers, Canopy Growth, and Les Serres Stephane Bertrand. Bertrand is a large-scale greenhouse operator located in Mirabel, Quebec, and the largest grower of pink tomatoes in the country. With guidance and assistance from Canopy Growth, the greenhouse has been upgraded and retrofitted for cannabis production and was licensed by Health Canada in May 2018.

As the company’s portfolio continues to develop, each constituent benefits from opportunities to collaborate with Canopy Growth and among themselves. Canopy Rivers believes this formula results in an ideal environment for innovation, synergy and value creation for Canopy Rivers, Canopy Growth and across the entire Rivers ecosystem.

Canopy Rivers is led by an experienced team of qualified financial and technical professionals with deep industry experience and relationship networks. The company’s acting CEO and chairman is Bruce Linton, CEO of Canopy Growth and founder of Tweed Marijuana.

Canopy Rivers Inc. (TSX.V: RIV), closed the day's trading session at $4.77, up 0.85%, on 724,083 volume with 1,249 trades. The average volume for the last 3 months is 498,655 and the stock's 52-week low/high is $2.40/$11.82.

Recent News

chart

Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF)

The QualityStocks Daily Newsletter would like to spotlight Green Growth Brands Inc. (OTCQB: GGBXF).

Green Growth Brands, Inc. (CSE: GGB) (OTCQB: GGBXF) is pleased to announce the opening of its first Seventh Sense CBD Shop at the Fayette Mall in Lexington, Kentucky. This location represents the first of hundreds of shops planned to serve customers at locations across the United States. 

Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF) is a lifestyle-oriented cannabis and cannabidiol (“CBD”) consumer products company with a portfolio of lifestyle brands customized to connect specific, like-minded customers. Each Green Growth Brand provides the best quality products within a retail experience that appeals to users in an environment that is emotionally branded and easy to navigate.

In the next five years, the cannabis industry will generate more than $28 billion of new revenue from an estimated 14 million new customers, according to Ackrell Capital’s 2018 Cannabis Investment Report. Meanwhile, Hemp Business Journal projects that the CBD market will increase 8x to $3 billion by 2021, up from $200 million in 2017. Green Growth Brand intends to dominate in these markets with a lineup up products grown, manufactured and presented with the highest quality standards in mind.

Products under the Green Growth Brand umbrella include:

  • CAMP: A kiosk-type store where consumers can experience beautifully crafted lifestyle products that enhance one’s journey to self-discovery.
  • Seventh Sense: A CBD-infused body care collection crafted from the finest botanicals and fragrances on earth. Created to maximize the properties and aromatics of each ingredient, Seventh Sense natural products are CBD-infused botanical therapy.
  • Meri+Jayne: Fiercely authentic and wholly unapologetic, Meri+Jayne is a youthful, full-on celebration of what makes each person unique. Expect the unexpected when it comes to this mix of amazing products.
  • Green Lily: A place for women to explore a new world of wellness. With advice on every product, from efficacy to usage, Green Lily guides guests through beautiful new ways to experience cannabis and CBD.
  • The +Source: Located in Las Vegas and Henderson, Nevada, The+Source dispensaries operated by Green Growth Brands serve both medical patients and retail customers. Green Growth Brands also operates a grow and production facility in Post, Nevada, and recently entered into definitive agreements to acquire a Pahrump, Nevada, cultivation facility.
  • XanthicBiopharms is the owner of valuable intellectual property that turns THC(Tetrahydrocannabinol) and CBD into a water-soluble substance. As a result of combining Green Growth Brands and Xanthic, this technology is being used to create incredible new products.

Business Strategy

Green Growth Brands has identified numeroushitches in the current cannabis retail space. The company intends to counter these challenges and provide a customer experience ripe with a friendly staff, in-stock assortments, efficient operations and more. The company’s retail partners provide distribution opportunities within 4,000 stores, as well as robust and established digital platforms to best reach the modern consumer.

Management

Green Growth Brands brings together a collection of expert retailers, scientists, botanists, developers, artists and business leaders for the benefit of building community. Led by an executive management team steeped in decades of experience with several of America’s most successful brands, including Victoria’s Secret, American Eagle Outfitters, Bath & Body Works, Limited Brands and Designer Shoe Warehouse, Green Growth Brands is uniquely positioned to create memorable brands, retail experiences, and quality products for the emerging cannabis industry.

Chief Executive Officer Peter Horvath heads strategy and execution across all company channels, and previously took shoe retailer DSW public on the NYSE at $1.5 billion. As a dynamic, creative brand leader, team builder, and specialty retail veteran with deep roots in finance, Horvath’s unique ability to understand the big picture while never missing the subtle details is a critical factor in Green Growth Brands’ success and brand popularity among customers.

Chief Marketing Officer Scott Razek is a brand strategist, storyteller and strategic marketer. Razek‘s 25 years of experience in brand building, product development and customer experience focus are a key differentiator for the Green Growth Brands portfolio.

CAO Ed Kistner brings 33 years of multifaceted experience at leading retail businesses, notably in finance, merchandise planning, operations and stores. His well-rounded experiences in fast-changing environments position Kistner to be the architect of the operational execution at Green Growth Brands.

CSO Kellie Wurtzman brings significant retail leadership to Green Growth Brands with a proven track record of leading high-performance stores and teams across multiple retail sectors. Her unmatched experience in identifying and supporting developing business opportunities is ideal for evolving the cannabis industry and will be instrumental in expanding operations at Green Growth Brands.

Headquartered in Columbus, Ohio, Green Growth Brands is traded on the Canadian Securities Exchange and on the OTCQB, providing investors with increased access to data, transparency and liquidity.

Green Growth Brands Inc. (OTCQB: GGBXF), closed the day's trading session at $4.4567, up 0.75%, on 296,505 volume with 777 trades. The average volume for the last 3 months is 191,444 and the stock's 52-week low/high is $1.8068/$5.205.

Recent News

chart

Pressure BioSciences Inc. (PBIO)

The QualityStocks Daily Newsletter would like to spotlight Pressure BioSciences Inc. (PBIO).

Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of high pressure-based instruments, consumables, and related services for the global life sciences industry, today released a short video that demonstrates its proprietary Ultra Shear Technology (“UST”) platform and its ability to create nanoemulsions (extremely small, nanometer-scale oil droplets that effectively dissolve in water) to provide optimized bioavailability for absorption. To view the full press release, visit: http://nnw.fm/LwOY3.

Pressure BioSciences Inc. (PBIO) develops, markets and sells proprietary laboratory instrumentation and associated consumables to the life sciences sample preparation market. Sample preparation refers to the wide range of activities that precede most forms of scientific analysis. It is often complex and time-consuming, yet a critical part of scientific research. The market for sample preparation products is currently estimated at $6 billion worldwide.

The Company’s product line can be used to exquisitely control the sample preparation process. It is based on a patented, enabling technology platform called pressure cycling technology (“PCT”). PCT uses alternating cycles of hydrostatic pressure between ambient (14.5 psi) and ultra-high levels (up to 100,000 psi) to safely and reproducibly control critical biological processes, such as the lysis (breakage) of cells, the digestion of proteins, and the inactivation of pathogens.

Pressure BioSciences’ product line is led by its newly released, next-generation Barocycler 2320EXTREME instrument. Named a finalist in the prestigious 2017 R&D Awards (also known as the “Oscars of Innovation”), the Barocycler 2320EXT is already being touted by some key opinion leaders as an essential element of the $1.8 billion U.S. “Cancer Moonshot” program. For example, Professor Phil Robinson, Co-head of the cancer research center of the Children’s Medical Research Institute (Sydney, Australia), said in a recent interview: “We are collecting the whole proteome on 70,000 tumor samples from all classes where complete clinical outcome is known. Due to its unique capabilities, the Barocycler 2320EXT has become a critical part of our program. It is the primary enabler of the high-throughput component of the project. Without this step, our project simply could not be done. In fact, the Barocycler 2320EXT works so well we have just purchased two more.”

Momentum is building when it comes to the potential for using the Company’s unique PCT technology platform. Leading scientists are intrigued by Pressure BioSciences’ approach, which among other attributes, revolutionizes the process of rupturing cells (lysis) for further study, yielding superior biomolecules for investigation. The Company’s technology transcends current methods of breaking open cells, which use chemicals, blades, metal beads, or other damaging and altering methods that can ultimately adversely affect the result for researchers. Pressure BioSciences’ PCT technology utilizes customized, controlled hydrostatic (water) pressure to rupture cells in a chamber, enabling exquisitely customized levels of pressure to optimally break open different types of cells at prescribed pressure levels—something never before accomplished in a commercial setting. Using this pioneering method, the result is a truer, more legitimate sample, which boosts the efficacy of research and the quality of results. The potential impact of this technology on scientific advancement is enormous, enabling research scientists to begin their studies with biological samples of unprecedented integrity, with the potential to improve research outcomes at the earliest, most critical step. PCT can additionally inactivate pathogens (e.g., viruses, bacteria) using hydrostatic pressure, making the samples safer to study—another innovation with astronomical potential for application in a variety of markets.

The Company’s high-pressure instruments for research purposes are marketed throughout the United States, Europe, China and Japan. To date, Pressure BioSciences has installed nearly 300 PCT Systems in over 165 leading academic, government, biotech and pharma laboratories around the world. Its primary applications are in biomarker discovery, forensics, agriculture and pathology. Over 100 scientific papers have been published on the advantages of the PCT platform, which is also being used in the specialized fields of drug discovery and design, bio-therapeutics characterization, soil and plant biology, vaccine development and histology.

Impressive as their biotech business is, there is more to the PBI story. Pressure BioSciences recently received two patents in China for its novel Ultra Shear Technology (UST), a process that has potential in a wide range of industrial applications, including extending the shelf life of some food products and making two insoluble liquids (like oil in water) soluble. Patents have also been filed in many other countries worldwide. UST is a novel technique based on the use of intense shear forces generated from ultra-high-pressure valve discharge.

This important technology has the potential to play a significant role in a number of commercially important areas through its ability to create high-quality, stable nanoemulsions. Scientific studies indicate that improved absorption, higher bioavailability, greater stability, lower surfactant levels and other advantages can be achieved with nanoemulsions – all hugely important factors in the fields of nutraceuticals, cosmetics, pharmaceuticals, and in various medical products. There is an enormous opportunity in the cannabis market, since the technology can potentially reduce oil droplets containing cannabidiol (CBD) to nanoparticles, after which they can be safely suspended in a stable water solution—something many companies have endeavored to achieve without success. Researchers looking for a way to increase the bioavailability of cannabinoids in the body will find this technology a game changer.

The Company’s UST technology also has possibilities in the production of clean label foods, which are currently processed using several innovative methods, including high-pressure treatments (such as Starbucks’ Evolution line of juices). In 2015, the worldwide market for high-pressure processed (HPP) food was estimated at U.S. $10 billion. UST uses ultra-high pressures and certain valves to generate intense shear forces under controlled temperature conditions to produce nanoemulsions, and which also significantly reduces food-borne pathogens. Pressure BioSciences’ initial focus with this technology will be to evaluate UST for the production of high-quality dairy products and beverages.

Pressure BioSciences Inc. (PBIO), closed the day's trading session at $3.20, up 46.12%, on 80,813 volume with 238 trades. The average volume for the last 3 months is 10,126 and the stock's 52-week low/high is $1.52/$5.00.

Recent News

chart

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP).

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) will conduct a comprehensive series of clinical studies on oral forms of nicotine delivery utilizing its DehydraTECH absorption platform. Under an investment agreement by its wholly owned subsidiary, Lexaria Nicotine LLC, a partner will provide $1 million toward research on nicotine consumer products that use DehydraTECH (http://nnw.fm/A0iyv).

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including nicotine and cannabinoids. To achieve higher absorption rates and fast onset, consumers traditionally defaulted to smoking. Lexaria provides a superior administration method by delivering these substances through a patented process within edible food products, thus eliminating all the harmful health consequences of smoking.

Lexaria’s technology is unique in that it takes advantage of GRAS (Generally Recognized As Safe) food ingredients processed with its patented DehydraTECHTM technology to improve taste, remove odor, and decrease the time to onset of bitter-tasting drugs. Lexaria is primarily a B2B enterprise and has existing cannabinoid licensing agreements with companies in Canada, the largest-market states in the United States, and internationally. Lexaria has entered into a R&D partnership with one of the largest cigarette companies in the world for oral forms of nicotine delivery. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within popular foods such as coffee, tea, and supplements. These brands include ViPova™ and TurboCBD™.

In 2015, Lexaria commissioned an independent third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company’s technological process and lipid formulation improve intestinal absorption as much as 500%. Lexaria has conducted multiple rounds of studies including in vivo and human clinical. In absorption studies conducted on rats, for example, Lexaria detected nicotine in the animal’s bloodstream just two minutes after it entered the stomach. In a randomized, double blinded human clinical study, cannabidiol (CBD) was measure in the human bloodstream at a 317% higher rate 30 minutes after swallowing a capsule processed with DehydraTECH than a non-enhanced capsule of equal strength.

Lexaria also has an R&D partnership with the Canadian government’s National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria’s unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D have helped support B2B relationships with Fortune 500 companies. Lexaria has four distinct subsidiaries that focus on different market sectors: Hemp/CBD; Pharmaceutical; Cannabis; and Nicotine.

Aside from testing, a critical component of Lexaria Bioscience’s business model is a strong and growing intellectual property portfolio. As of the end of 2018, the company’s patent portfolio includes 53 patent applications filed and pending in more than 40 countries around the world; and 10 patents granted to date. Lexaria is expecting additional new patent awards both in the U.S. and internationally in 2019 and beyond. Some of its more recent areas of investigation have included human hormones and erectile dysfunction substances, among others.

Royalties play a vital role in Lexaria’s revenue-generating business model. The company out-licenses its technology (royalty) to third-partners and has signed royalty deals with start-up companies as well as with a Fortune 100. The company’s growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has contributed to several multi-hundred million-dollar valuations over the course of his career. He is supported by a growing team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets.

Lexaria Bioscience Corp. (LXRP), closed the day's trading session at $1.37, up 3.79%, on 98,341 volume with 133 trades. The average volume for the last 3 months is 182,081 and the stock's 52-week low/high is $0.75/$2.43.

Recent News

chart

Cannabis Strategic Ventures, Inc. (NUGS)

The QualityStocks Daily Newsletter would like to spotlight Cannabis Strategic Ventures, Inc. (NUGS).

CannabisNewsWire ("CNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring Cannabis Strategic Ventures (OTC: NUGS), a client of CNW focused on incubating, developing and partnering with category leaders within the cannabis sector. To view the full publication, titled “Cannabis Cultivators Profit from Growing Legal Market,” visit: http://cnw.fm/m0vAk.

Cannabis Strategic Ventures, Inc. (NUGS), headquartered in Los Angeles, California, is focused on supporting entrepreneurial growth within the fast-growing legal cannabis sector. Through a selective portfolio of subsidiaries, Cannabis Strategic Ventures offers outsourced personnel solutions tailor-made to match the growth dynamics of cannabis cultivators, manufacturers, dispensaries and other cannabis marketplace participants. The company also pursues investment opportunities in the areas of real estate, cultivation, extraction, distribution, packaging, dispensary operations, and branded products within the cannabis space.

The legalization of adult-use sales in California is expected to create nearly 99,000 cannabis industry jobs in the state by 2021, representing about a third of all cannabis jobs nationwide, and 146,000 jobs overall when indirect and induced efforts are considered, according to Arcview Market Research. By 2021, direct cannabis industry employment will top 291,500 FTE jobs, with a total employment effect of nearly 414,000 FTEs across all legal cannabis states, according to the report.

Cannabis Strategic Ventures believes its staffing capabilities will be in a similar state of demand. The company in April 2018 completed a definitive agreement to acquire Worldwide Staffing Group, Inc., which booked approximately $1.5 million in revenues in 2017.

Worldwide will operate within Cannabis Strategic Ventures as an independent and separate wholly owned subsidiary providing strictly non-cannabis related employment and staffing services. As Worldwide continues to expand its operations in general clerical and administrative, marketing, accounting, and other verticals, Cannabis Strategic Ventures will leverage the subsidiary’s expertise to expand its business operations further into the cannabis staffing arena, with an emphasis on the California markets.

Cannabis Strategic Ventures’ BudHire™ subsidiary is an outsourced employment service specifically designed to meet the needs of growing cannabis-related business operations, utilizes a proven recruiting formula to match the most qualified candidates to a broad spectrum of cannabis-related jobs. Under the BudHire™ brand, Cannabis Strategic Ventures offers temporary, seasonal, permanent staffing solutions, as well as professional employment organization services and human resources consulting to the cannabis industry.

Cannabis Strategic Ventures portfolio also includes Pure Applied Sciences Inc. and its brand “PureOrganix™,” a line of high quality concentrate, organic and pure cannabis oils that conform with Current Good Manufacturing Practices (cGMP) and meet FDA guidelines for Active Pharmaceuticals Products (API). The acquisition includes all intellectual properties, including formulations and technologies, and related accessories of Pure Applied Sciences.

Cannabis Strategic Ventures Pure Applied Sciences subsidiary, has a cannabis concentrate extraction services agreement with CP Logistics LLC (“CPL”), a wholly owned U.S. subsidiary of Sunniva Inc. (CSE:SNN) (OTCQX:SNNVF). Under this agreement, CPL will perform white label services producing high quality, ultra-purified cannabis extracts out of its Sun-Oil Facility in Cathedral City, California, for Pure Applied Sciences under the Pure Organix brand name.

The management team at Cannabis Strategic Ventures believes there is incredible opportunity to carve-out and control specific industry niches, to create unique cannabis consumer branded products, and to expand into other sub-sectors of the cannabis marketplace.

Cannabis Strategic Ventures, Inc. (NUGS), closed the day's trading session at $1.36, up 1.49%, on 105,213 volume with 125 trades. The average volume for the last 3 months is 115,268 and the stock's 52-week low/high is $1.02/$5.94.

Recent News

chart

Earth Science Tech, Inc. (ETST)

The QualityStocks Daily Newsletter would like to spotlight Earth Science Tech, Inc. (ETST).

Earth Science Tech, Inc. (OTCQB: ETST) (“ETST" or the “Company"), an innovative biotech company focused on the cannabidiol (CBD), nutraceutical and pharmaceutical fields, medical devices, and research and development, today announces a distribution agreement to market its Hygee™ medical device in Vietnam, as well as provides an update on its CBD product line.

Earth Science Tech, Inc. (ETST) is an innovative biotechnology company operating in the fields of hemp cannabinoid (CBD), nutraceutical, pharmaceutical and medical device research and development. Earth Science Tech offers the highest purity and quality, full-spectrum, high-grade hemp CBD (cannabidiol) oil on the market. Made using the supercritical CO2 liquid extraction process, the company’s CBD oil is 100 percent natural and organic. Earth Science Tech has partnered with the University of Central Oklahoma and DV Biologics Laboratory to conduct research and development projects that scientifically support and advance the healthcare benefits of its high-grade hemp CBD oil.

Earth Science Tech Inc. currently has three wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors. These subsidiaries include:

  • Earth Science Pharma, Inc., which is committed to development of low cost, noninvasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. Earth Science Pharmaceutical CEO and chief science officer Michel Aubé is leading the company’s research and development efforts. The company’s first medical device, MSN-2, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. Earth Science Pharma is working to develop and bring to market medical devices and vaccines that meet the specific needs of women.
  • Cannabis Therapeutics, Inc. (“CTI”), which is poised to take a leadership role in the development of new, leading-edge, cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds a provisional application patent for a CBD product that is focused on developing treatments for breast and ovarian cancers.
  • KannaBidioiD (“KBD”) provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused edibles and vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy.

Earth Science Tech celebrated a significant, developmental year during 2017 by sharing its achievements in a condensed end-of-year report. Among the report’s highlights are the implementation of a development plan for the coming three years, which includes expanding into Canada and opening new manufacturing and shipping facilities. Of particular interest is the acquisition of Canna Inno Laboratories Inc., a company headquartered in Montreal, Quebec, Canada, which gives Earth Science Tech access to Canadian government grants offered to innovators in the pharmaceutical industry. ETST has also launched development of proprietary prophylactic therapies utilizing cannabidiol (CBD) to treat various forms of breast cancer.

In October 2017, ETST announced it is cooperating with the Clinique SIDA Amité (AIDS Friendship Clinic) for a mini-clinical trial, the last trial needed before the MSN-2 device, designed for the detection of STIs, enters molecular diagnostic trials. And in November 2017, the company began pre-launch human trials on a new CBD formula to fight against the U.S. opioid epidemic. The new formula, expected to decrease cravings and the negative effects of withdrawal in addicts, is based on industrial hemp CBD mixed with a known natural ingredient proven to help increase dopamine levels. ETST’s medical devices will first be launched in Vietnam, Djibouti and Morocco while the company awaits regulatory permission to enter the North American market.

The company expects to up-list to the OTCQB in early 2018, which management believes will attract well-funded institutional investors and pave the way to becoming the next billion-dollar-in-capitalization company on the OTC markets. Other highlights include completion of the company’s Scientific Advisory Council with a team of recognized scientists, the launching of several CBD-infused edible products and entry into the medical devices market through collaborative partnerships.

Earth Science Tech has signed a collaborate agreement with Laboratories BNK Canada, a private laboratory that will conduct the clinical studies necessary for MSN-2 medical device-related services to meet regulatory requirements. ETST has confirmed the MSN-2 device’s ability to detect chlamydia, and is working to validate similar results for gonorrhea, both highly infectious diseases that often have permanent consequences for patients. ETST will also add testing for trichomoniasis and a complete body fluid panel to detect the different serotypes of the human papillomavirus (HPV) that causes cervical cancer. These additions will help the company create sales opportunities in the global market for diagnostic testing of STDs that Transparency Market Research has indicated will grow to $108 billion by 2019.

Cannabis Therapeutics is in the development stage of two cannabinoid-based pharmaceutical drugs and three cannabinoid-based nutraceutical products targeting a variety of ailments such as anxiety, depression, triple negative breast cancer, and fatty liver disease, among others. Research into the benefits of the non-psychoactive cannabinoid molecules found in the cannabis plant is supported by ETST’s International Application for Provisional Patent titled “Cannabidiol Compositions Including Mixtures and Uses Thereof,” which was filed on October 8, 2015. Cannabis Thera’s R&D efforts are concentrated on developing CBD-based drugs and nutraceutical products and in working to integrate the CBD molecule with existing generic drug molecules to create more efficient medications with fewer and less severe side effects. A report in Hemp Business Journal predicts the CBD consumer market will grow to $2.1 billion by 2020, while other industry experts expect an increase to almost $3 billion by 2021. A recent report by Statista projects the U.S. consumer market for cannabinoid-based pharmaceuticals could reach $50 billion by the year 2029.

The management team at Earth Science Tech brings decades of invaluable experience to the nutraceutical, dietary supplement field as well as the life sciences sectors. Nickolas S. Tabraue, who serves as the president, director and chief operating officer, is an industry veteran with extensive knowledge of supplements, retail management, customer service and sales expertise. He is joined by CEO and CSO Dr. Michel Aubé, a microbiologist whose scientific research in sexually transmitted infections, cancer and stem cell biology has been widely published in several prestigious medical journals. Sergio Castillo, chief marketing officer, and Gabriel Aviles, chief sales officer, bring a wealth of marketing and sales experience to Earth Science Tech, which is complemented by Issa El-Cheikh, Ph.D., and his 25 years in the international finance, accounting, planning and execution of large scale transactions in the public and private sectors.

Earth Science Tech’s products include CBD, a natural constituent of hemp oil derived from hemp stalk and seed. EST offers CBD in the form of vitamins, minerals, herbs, botanicals, personal care products, homeopathies, functional foods and other products delivered in such forms as capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders and whole herbs. Earth Science products can be found at retail stores throughout the United States and are available for purchase through the internet.

Earth Science Tech, Inc. (ETST), closed the day's trading session at $0.76, up 3.55%, on 25,447 volume with 22 trades. The average volume for the last 3 months is 33,381 and the stock's 52-week low/high is $0.421/$2.45.

Recent News

chart

Kontrol Energy Corp. (CSE: KNR) (OTC: OTSHF) (FSE: 1K8)

The QualityStocks Daily Newsletter would like to spotlight Kontrol Energy Corp. (CSE: KNR).

Kontrol Energy Corp. (CSE: KNR) (OTCQB: KNRLF) (FSE:1K8) (the "Company" or "Kontrol") is pleased to announce that its common shares are now trading on the OTCQB Venture Marketplace (the "OTCQB Venture"), a US trading platform that is operated by the OTC Markets Group in New York. The Company will trade on the OTCQB Venture under symbol "KNRLF"; the Company's common shares will continue to trade on the Canadian Securities Exchange under the symbol "KNR" and on the Frankfurt Exchange under symbol "1K8". Also today, NetworkNewsWire released a report on the company detailing how Kontrol Energy has joined the global marketplace with its latest Internet of Things (“IoT”) technology, aptly named Smartmax Energy Gateway. This intuitive technology will allow Kontrol Energy to meet demands for commercial, multi-residential and hospitality real estate markets around the world, creating abundant new growth opportunities.

Kontrol Energy Corp. (CSE: KNR) (OTC: OTSHF) (FSE: 1K8) specializes in the integration of smart energy technologies and solutions for North American commercial and industrial property owners and operators to help them benefit from energy cost savings and minimize greenhouse gas emissions. Kontrol is a leader in the energy efficiency sector through IoT, Cloud and SaaS technology and is ranked by Canadian Business and Maclean’s as the 7th fastest growing startup in 2018.

Kontrol’s leadership position is reshaping the way customers use, manage and strategically allocate energy resources to realize immediate energy savings by gaining more control over energy consumption and demand in real-time.

As the fastest growing global “fuel source,” energy efficiency is big business with industry analysts noting this multi-trillion-dollar market offers significant opportunities over the next five years. Established market segments include: energy retrofits ($71.4 billion); distributed generation ($179.9 billion); energy analytics ($33.5 billion); and greenhouse gas/carbon measurement, reduction ($1.2 trillion). Each $1 invested in energy efficiency displaces up to $3 of utility-scale transmission and distribution investment, according to the International Energy Agency.

Formed in 2015 by a group of energy veterans who recognized that the energy efficiency industry is one of the fastest growing fuel sources for the global economy, Kontrol is committed to enhancing and improving its customers sustainability objectives. In less than two years, Kontrol has grown its revenue run rate to $16 million from $1.8 million, delivering on stated goals and objectives as it seeks to continue this pattern through accretive acquisitions and the expansion of the company’s smart energy technologies.

Up to 50 percent of Kontrol’s overall revenues are recurring annually, and the company’s 2019 outlook includes strategic initiatives that will expand the company’s smart energy technologies to U.S. markets, bring additional accretive and strategic acquisitions, and accelerate recurring SaaS revenues.

Kontrol’s strategy of disciplined mergers and acquisitions includes the following highlights:

  • Acquisition of Log-One Ltd.’s award-winning energy conservation technology, Energy Management System (“EMS”), an intelligent, occupancy-based heating and air-conditioning control system for commercial and multi-residential real estate. Rebranded as Kontrol EMS Technology, the company has added IoT and mobile application capabilities, creating a recurring revenue platform through a Software-as-a-Service (SaaS) platform.
  • Acquisition of ORTECH Consulting Inc., an engineering consulting firm specializing in Greenhouse Gas (GHG) reporting, emission testing, air quality testing and renewable energy/power consulting.
  • Acquisition of Efficiency Engineering Inc. (“EE Inc.”), which provides engineering services to industrial, municipal and commercial building owners across Canada. EE Inc. provides detailed energy efficiency analysis, energy audits, management of facility system solutions, electrical and mechanical design and energy conservation studies.
  • Acquisition of MCW Dimax Ltd. (“MCX”), a firm specializing in solutions for the application of energy software to analyze the management of complex heating, ventilation and cooling systems for large residential, commercial, and mission critical real estate owners.
  • Acquisition of CEM Specialties Inc. (“CEMSI”), a market leader in turn-key emission monitoring, equipment and solutions.

The company has also established entry into the North American cannabis market as a supplier of integrated energy efficiency solutions and technologies. Within this market, Kontrol is focused on assisting cannabis growers to reduce the cost of energy and support mission critical infrastructures. To date, Kontrol has secured two contracts to provide energy efficiency services with Licensed Producers in the Canadian cannabis sector.

The Kontrol Energy group of companies is currently saving its customers more than 40 million kilowatt hours of electricity per annum and providing a corresponding reduction in GHG emissions.

Kontrol’s management team includes CEO Paul Ghezzi, a leader in clean tech, renewable energy development, solar project financing and distributed generation. Ghezzi has global experience in power generation projects under Feed-in Tariff programs and Power Purchase Agreement programs for both commercial and utility-scale projects. COO Kristian Lavereau has more than 25 years of experience in the IT solutions (analytics and mobile computing), energy optimization and efficiency (intelligent control systems, solar PV, lighting). Claudio Del Vasto, CPA, CA | CFO, is a senior finance executive with an extensive background in corporate finance, strategy and business development.

Kontrol Energy Corp. (CSE: KNR), closed the day's trading session at $0.62, up 3.33%, on 10,000 volume with 7 trades. The average volume for the last 3 months is 17,170 and the stock's 52-week low/high is $0.46/$1.35.

Recent News

chart

Choom Holdings Inc. (CSE: CHOO) (OTC: CHOOF)

The QualityStocks Daily Newsletter would like to spotlight Choom Holdings Inc. (CHOOF).

Choom™ (CSE: CHOO; OTCQB: CHOOF) is pleased to announce that it has entered into a letter of intent agreement ("LOI") with one of the 25 Cannabis Retail lottery winners to open a location in Ontario. Choom, an emerging adult use cannabis retailer, is building out one of the largest retail cannabis networks in Canada. The LOI is with a winner of one of the 25 retail opportunities to apply for a license to operate a cannabis retail store granted as a result of the Alcohol and Gaming Commission of Ontario's ("AGCO") Expression of Interest Application Lottery conducted on January 11, 2019. Also today, the company was highlighted in an article examining how cannabis thrives in a world of dwindling brick and mortar retail.

Choom Holdings Inc. (OTC: CHOOF) (CSE: CHOO) channels the laid-back spirit of Hawaii to the Okanagan region of British Columbia with a generous nod to the inspirational, yet unofficial, history of the 1970s “Choom Gang,” a group of buddies in Honolulu (including former President Barack Obama) who knew how to relax with “choom,” the local’s term for marijuana. Choom’s trademark slogans pivot off another unconventional phrase (“Say Hello to…”), bringing a heady dose of good times and good friends together as the company invites investors to “Say Hello to Choom™” as it lights up the adult recreational cannabis market in Canada.

Choom™ has been an ACMPR (Access to Cannabis for Medical Purposes Regulations) applicant since November 2013 in Vernon, B.C. The company’s first application has received security clearance and is now in the detailed review stage. They also recently announced their second late-stage ACMPR application, which is in its confirmation of readiness stage. Cannabis Compliance Inc. has been retained to help expedite Choom’s initial license applications to ensure the company’s readiness for legalization of recreational marijuana in Canada mid-summer 2018.

True to the company’s character, Choom™ is retrofitting two large facilities – No. 1 in Vernon, B.C., and No. 2 on Vancouver Island – to house its cannabis growing facilities. Phase 1 of the Vernon property will provide Choom™ with 6,800 square feet of growing space, capable of producing 660 kg/year of cannabis at an estimated revenue of $6.6 million, excluding oils. The company expects this facility to be completed by July 2018, the same month that Canada is expected to formally legalize recreational marijuana for adult use. A potential Phase 2, to be completed by the end of 2018, would add another 6,800 square feet for a total of 1,500 kg/year capacity, which would nearly double No. 1’s revenue. A Level 9 vault is also planned with a storage capacity of 15,000 kg. While the No. 2 facility on Vancouver Island is smaller – 4,500 square feet – its retrofit is also slated to be completed by July 2018. Plans include doubling this space as well, which would add about $9 million in annual revenue, excluding cannabis oils.

Choom™ announced its retail dispensary strategy with the intention of establishing market leadership in reaching the Canadian cannabis consumer. The partner program is already in the retail space design stage as the company seeks to build a chain of branded retail cannabis dispensaries in jurisdictions in Canada where recreational cannabis is legal. Choom™ Stores will have a cool, modern layout and design created to emit an authentic “Aloha” vibe. Choom™ is all about producing high-grade cultivars and curating them for a bigger audience.

A savvy, experienced management team includes Chris Bogart, president and CEO; John Oh, R.P.I.C., Operations Manager; Robert Bayrack, Master Grower, S.P.I.C.; and Adrian Robinson, Strategic Advisor. Bogart has over two decades of international experience in capital markets and was a co-founder of InMed Pharmaceuticals and Magnum Uranium. He has structured complex equity financing transactions in the U.S., Europe and Canada. Bogart is joined on the Board of Directors by Kevin Pull, Stephen Tong and John Oh.

While the medical marijuana industry is expected to double by 2021 to 500,000 registered users, the true highlight of the recreational cannabis represents the key cultural shift set to launch in Canada. With an estimated $4.9B to $8.7B retail market coming, now is the right time for a Recreation Brand like Choom™ to be involved in this growing industry. Establishing and maintaining Choom™ premium brand loyalty is a key factor in the company’s growth strategy. Get ready to “Say Hello” to opportunity, good times and good friends with Choom™.

Choom Holdings Inc. (CHOOF), closed the day's trading session at $0.3679, up 0.45%, on 1,103,109 volume with 398 trades. The average volume for the last 3 months is 317,385 and the stock's 52-week low/high is $0.285/$1.129.

Recent News

chart

Cyberfort Software, Inc. (CYBF)

The QualityStocks Daily Newsletter would like to spotlight Cyberfort Software, Inc. (OTC: CYBF).

Cyberfort Software Inc. (OTC: CYBF) was featured today in a publication examining how, between 2015 and the second quarter of 2018, Reuters reported cyberattacks surged more than 100 percent.

Cyberfort Software, Inc. (CYBF) is a cybersecurity technology company specializing in the acquisition and development of security software, content filtering, and ad blocking technology. Headquartered in San Francisco, California, Cyberfort Software is actively dealing with various cyber threats through the development of innovative protection technologies designed for mobile, personal and business tech devices across multiple platforms.

Committed to the idea that everyone – from individuals to global corporations – should be able to enjoy a digital future free of malicious attacks robbing them of privacy and security, Cyberfort is working to strengthen its portfolio of cybersecurity IPs and stay one step ahead of cyberthreats. The growing plethora of tech devices enveloping everyday life opens the door to increasing cyberattacks through a stunning array of sophisticated cyberthreats. Protecting organizations and individuals with proactive security postures and protective measures is a key component of Cyberfort’s strategy to develop cybersecurity solutions that are smart, simple and efficient.

The company’s 2016 purchase of Vivio, a provider of pioneering AI content filtering and software protection, underscores Cyberfort’s commitment to cybersecurity. Vivio, an iOS 10 ad blocking app, currently serves over 10,000 unique users across iPhone, iPad and Mac. Vivio makes web browsing better, faster and more satisfying by blocking ads and reducing data usage, which also helps save battery life. Continuous ad blocking rule updates are delivered via an Intellectual Property Cloud-based autonomous engine with ad blocking tracker and malware detection filters.

Cyberfort recently signed a letter of intent to acquire Just Content Software which includes the Just Content app, software and underlying source code. Just Content is an efficacious and multi-functional ad blocking app that safeguards families and businesses with proprietary “Home Safe Filter” and “Business Filter” products. The Just Content app is available on iTunes and protects against unsafe links, adult content, phishing sites and inflammatory hate speech found on the internet, among other potential backdoor attacks and cyberthreats. A due diligence review is underway and a final determination regarding this acquisition is anticipated within weeks.

“Cyberfort aims to become a leader in developing cutting edge ad-blocking protective software that keeps the internet safe for families and business, which in our highly technological and immediate information-access society is a significant concern. Acquiring Just Content furthers our commitment to provide the best and most effective ad-blocking software in the marketplace,” says Cyberfort CEO Daniel Cattlin.

Favorable government regulations promoting tightened web security is a major factor driving adoption of web content filtering solution along with the public’s growing desire to better manage network bandwidth consumption and protect their online security and privacy. Cyberfort’s objective is to protect the data and integrity of personal and business computing assets and defend those assets against any threat or attack. The company’s software also offers symbiotic ad-blocking capabilities to complement its cyber defense effectiveness.

As Cyberfort continues to innovate, the Vivio team intends to leverage the current user base as a sandbox to test and optimize future incremental developments targeting an enterprise suite of tools that can be integrated into sector specific areas of growth. Key areas of focus include mobile device management, bring your own device (“BYOD”), mobile app management and secure mobile browser.

The Cyberfort leadership team is headlined by Cattlin, who offers a new age perspective to the business with expertise in project and asset management and a background in corporate finance. Cattlin brings both the operational and financial understanding to take companies from start-up and early development to expansion and capital growth within a public environment.

Chief Technology Officer Tomas Mistrik helped his team deliver a variety of technological products including the Vivio ad-blocking app for iOS 10 and the Silicon Valley-based Synergykit platform for mobile developers.

Technology Development Manager Krishna Kumar brings more than 10 years of experience in the Information Technology industry where he provided powerful security and ad-blocking measures for companies such as CSC and PayPal India.

Senior Advisor Harish Doddala brings nine years of product management and software engineering experience, delivering results for Cisco, VMware, Oracle, IBM and Siemens.

Cyberfort Software, Inc. (OTC: CYBF), closed the day's trading session at $0.2275, up 13.75%, on 67,451 volume with 42 trades. The average volume for the last 3 months is 17,936 and the stock's 52-week low/high is $0.051/$69.00.

Recent News

chart

BriaCell Therapeutics Corp. (OTC: BCTXF) (TSX.V: BCT)

The QualityStocks Daily Newsletter would like to spotlight BriaCell Therapeutics Corp. (BCTXF).

On February 12, 2019 Jamieson Bondarenko, a recently appointed member of BriaCell Therapeutics’ (OTCQB: BCTXF) (TSX.V: BCT) Board of Directors, acquired 2,000,000 common shares of the company through the facilities of the TSX Venture Exchange at a price of $0.0975 per share for a total purchase price of $195,000. To view the full press release, visit: http://nnw.fm/h6LXR.

BriaCell Therapeutics Corp. (OTC: BCTXF) (TSX.V: BCT), based in Berkeley, CA, and headquartered in Vancouver, British Columbia, is a clinical-stage biotechnology company focused on the development of targeted immunotherapy for advanced breast cancer.

BriaCell hopes to develop and market the first off-the-shelf personalized immunotherapy for the treatment of advanced breast cancer.

The results of two previous proof-of-concept clinical trials produced encouraging results in patients with advanced breast cancer. Most notably, one patient with breast cancer that had spread to other sites (metastatic cancer) responded to Bria-IMT™ with a substantial tumor shrinkage in multiple sites including the breast, the lung, soft tissues and even the brain. Similar observations have been confirmed more recently in additional patients, and BriaCell is developing BriaDX™ as a way to identify those patients most likely to respond.

BriaCell has recently completed recruitment of a Phase I/II study (NCT03066947) of Bria-IMT™, the Company’s lead product candidate, in advanced breast cancer patients showing an outstanding safety profile and excellent efficacy. BriaCell is currently enrolling advanced breast cancer patients in a combination therapy trial (NCT03328026) of Bria-IMT™ with Keytruda® (Keytruda® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.) or Yervoy® (Yervoy® is a registered trademark of Bristol-Myers Squibb Company). For further information on the Phase IIa clinical trials, please visit trial NCT03066947 and trial NCT03328026.

BriaCell’s pipeline also includes Bria-OTS™, the first off-the-shelf personalized immunotherapy for advanced breast cancer; and, a companion diagnostic product BriaDX™. By using BriaDX™ to identify and treat the patients who would most likely benefit from their immunotherapies, BriaCell expects to personalize the treatment for the patients, and bring hope to thousands of cancer patients who currently have few-to-no treatment options.

Breast Cancer Statistics

The National Cancer Institute estimates that more than 265,000 new cases of female breast cancer will be diagnosed in the U.S. during 2018, and that more than 40,000 women in the U.S. will die from the disease. Approximately 12 percent of women will be diagnosed with breast cancer at some point during their lifetime, based on 2013-2015 data.

Using its novel technology platform and strong R&D capabilities, BriaCell believes it has the opportunity to address this market, as well as have the opportunity to develop immunotherapy candidates for other cancer indications.

The global cancer immunotherapy market is expected to reach nearly USD$203 billion by 2025.

BriaCell Therapeutics Corp. (BCTXF), closed the day's trading session at $0.0795, up 13.57%, on 200,656 volume with 5 trades. The average volume for the last 3 months is 16,118 and the stock's 52-week low/high is $0.049/$0.135.

Recent News

chart

Black Iron Inc. (TSX: BKI) (OTC: BKIRF) (GR: BIN)

The QualityStocks Daily Newsletter would like to spotlight Black Iron Inc. (TSX: BKI) (OTC: BKIRF) (GR: BIN).

NetworkNewsAudio (NNA), a NetworkNewsWire (NNW) Solution that delivers clients unparalleled visibility, recognition and brand awareness in the investment community, today announces the online availability of its interview with Black Iron Inc. (TSX: BKI) (OTC: BKIRF) (GR: BIN), a client of NNW and iron ore exploration and development company advancing to production its low cost, high purity grade iron ore project in Central Ukraine. The interview can be heard at http://nnw.fm/bMI45.

Black Iron Inc. (TSX: BKI) (OTC: BKIRF) (GR: BIN) is a Canadian iron ore exploration and development company advancing to production its wholly owned Shymanivske Iron Ore Project, located in Krivyi Rih, Ukraine. Black Iron’s Shymanivske project is situated in the southern part of the historic KrivBass iron ore mining district, a highly developed iron ore mining region with well-established infrastructure and nearby skilled labor forces. Surrounded by seven producing iron ore mines, the Shymanivske project will produce an ultra-high-grade, 68-percent iron ore concentrate with few impurities at very low cost.

The Market

Iron ore concentrates are one of the essential raw materials used by the steel industry to either make sinter or highly valued pellets. Black Iron’s concentrate can be used in either application and is an ideal source to make pellets since it does not need to be ground finer and contains very few impurities. According to the CRU Group, an internationally recognized top global business intelligence provider and consultancy specializing in commodities, there is a growing global shortage of pellet feed resulting in a supply/demand gap of 133Mt against the current base of approximately 400Mt consumed by 2035. According to a recent report issued by Zion Market Research, the global iron ore pellets market was valued at around US$25.22 billion in 2017 and is expected to reach US$50.12 billion by 2024, growing at a compound annual growth rate (CAGR) of 8.1 percent between 2018 and 2024 (http://nnw.fm/2vaDR).

Countries around the world, most notably China (http://nnw.fm/Je8gs), have instituted regulatory changes to curb polluting emissions from steel mills through numerous methods, including encouraging a shift to higher grade iron feed products such as pellets as less coal needs to be burnt per ton of steel produced.

Shymanivske Project

Black Iron’s Shymanivske’s project, which is expected to produce ultra-high-grade 68 percent iron content pellet feed iron concentrate, is generating significant interest from steel mills and global commodity trading houses. Use of ultra-high-grade 68-percent iron content product in the production of steel is a value-added product to customers since it increases blast furnace productivity and reduces greenhouse gas emissions generated per ton of steel produced.

The project’s proximity to rail lines (1 mile), electrical power (20 miles), sea ports (140 to 260 miles) and a skilled workforce (6 miles) significantly reduces the up-front construction costs and allows for the mine to be built in a phased approach. The Shymanivske project has been ranked by the CRU Group in the lowest position of the business cost curve for pellet feed projects currently under development and as the second lowest in capital intensity (construction capital divided by annual production) within CRU Group’s extensive database (http://nnw.fm/3MXsT). This low-cost position makes the project economics very robust to any shocks in iron ore price while providing a very high return at current and forecast prices.

Black Iron continues to advance its project on several fronts including construction funding and off-take agreements (http://nnw.fm/tQ4g2). Discussions with Ukraine’s Ministry of Defense to transfer a parcel of land required by the company for location of its processing plant, waste rock and tailings are nearing finalization, as are discussions with the Kryviy Rih City Council to lease a portion of the surface rights currently under that body’s control. The recent engagement of Ivan Markovich as Black Iron’s Vice President of Government and Community Relations will assist the company in these endeavors given his extensive network of relationships with senior Ukraine government officials.

The Shymanivske project holds a mining allotment permit for a large iron ore deposit with a NI 43-101 compliant resource estimated to contain 646 Mt (million tons) Measured and Indicated mineral resources, consisting of 355 Mt Measured mineral resources grading 31.6% total iron and 18.8% magnetic iron, and Indicated mineral resources of 290 Mt grading 31.1% total iron and 17.9% magnetic iron, using a cut-off grade of 10% magnetic iron. Additionally, there are 188 Mt of Inferred mineral resources grading 30.1% total iron and 18.4% magnetic iron.

Full mineral resource details and project economics can be found in the NI 43-101 compliant technical report entitled “Preliminary Economic Assessment of the Re-scoped Shymanivske Iron Ore Deposit” effective November 21, 2017, under the Company’s profile on SEDAR at?www.sedar.com.

Management

Black Iron’s management and board of directors is stacked with experts well-versed in successfully building and operating iron ore projects. CEO Matt Simpson, P.Eng. is the former general manager of Mining for Rio Tinto’s Iron Core Company of Canada and worked for Hatch designing global metallurgical refineries. He is also a Qualified Person as defined by NI 43-101. Chairman Bruce Humphrey is the former COO of GoldCorp and former chairman of Consolidated Thompson Iron Ore mines which was sold to Cliff’s resources for US$4.9 billion.

Les Kwasik, COO, has over 40 years of hands-on experience building and operating mines globally with companies such as INCO (VALE) and Xstrata (Glencore). Paul Bozoki, CFO, is the former CFO of CD Capital Partners, operating in the Ukraine. Bill Hart, senior vice president of corporate development, has over 30 years of experience selling iron ore while working for Rio Tinto, Cliffs Natural Resources and most recently Roy Hill Holdings Ltd. Ivan Markovich was recently engaged in the capacity of Black Iron’s vice president of Government and Community Relations to leverage his extensive network of relationships with senior Ukraine government officials.

Black Iron Inc. (BKIRF), closed the day's trading session at $0.0662, up 1.38%, on 142,326 volume with 15 trades. The average volume for the last 3 months is 13,713 and the stock's 52-week low/high is $0.0285/$0.0939.

Recent News

chart

Golden Developing Solutions, Inc. (DVLP)

The QualityStocks Daily Newsletter would like to spotlight Golden Developing Solutions, Inc. (DVLP).

Golden Developing Solutions, Inc. (DVLP) was highlighted today in a publication from Investorideas.com looking at growing demand for higher extraction outputs and how the CBD industry is responding.

Golden Developing Solutions, Inc. (DVLP), an emerging leader in ancillary software and the cannabidiol (CBD) products marketplace, provides business services and/or products supporting the cannabis industry including an online retail business for CBD, hemp oil and health/wellness related products.

Global acceptance of cannabis and related CBD products continues to increase as North America advances toward favorable legislation. Canada legalized recreational cannabis in October 2018, and the United States has 30 states and the District of Columbia allowing either recreational or medical cannabis, or both. Voters in four additional U.S. states will consider marijuana initiatives on the November 2018 ballot. The global legal cannabis market is projected to reach USD$146 billion by the end of 2025, with a greater acceptance of medical cannabis products as a driving factor, according to Grand View Research.

DVLP is taking advantage of consumer demand for CBD products through its wholly owned Pura Vida Vitamins, LLC subsidiary, which recently launched a direct-to-consumer website (www.PuraVidaVitamins.com) and commenced sales of Pura Vida branded products. Pura Vida merchandise includes hemp and CBD-related products and other products focusing on health and lifestyle which are available through established wholesale and distribution channels. In addition, a line of CBD pet supplements and other products are in development.

DVLP recently acquired “Where’s Weed” (Layer Six Media LLC DBA “Where’s Weed”) and its primary asset, WheresWeed.com. Where’s Weed is an American cannabis technology company known for connecting medical and recreational cannabis users with trusted local marijuana businesses in their communities. As a rapidly growing community-based online resource for cannabis consumers with a host of user-friendly services, Where’s Weed offers a sophisticated mobile app with strong traction and powerful growth potential as the North American legal cannabis market continues to expand exponentially.

WheresWeed.com has a large and expanding reach with nearly 3 million pageviews per month. In addition, the WheresWeed mobile app, available in both iOS and Android, has been downloaded over 80,000 times, proving to be complementary to DVLP’s objective to capitalize on the massive growth curve in the marijuana space.

“The huge flood of new growers and producers is likely to create oversupply in the near term, narrowing margins for major producers,” says DVLP CEO Stavros Triant. “However, this should actually increase the net number of new consumers in the marketplace, further reinforcing the enormous growth potential for hub service providers in the space that are situated on high-traffic internet real estate, which is exactly how we view the Where’s Weed property.”

The company’s move into the lucrative C-store snack market was solidified with a material purchase order for CBD oils from a major distributor specializing in the snack foods and accessories to the convenience store and gas station market. The order represents significant progress as DVLP gears up its ready-made snack distribution strategy for its CBD products.

“We are extremely excited about the launch of our CBD product line with this distributor,” Triant states. “The C-Store strategy dovetails perfectly with our direct marketing strategy through our primary online retail channel, and we have indications from the distributor that, if this initial test order goes well, successive Purchase Orders could be significant and underpin strong sales growth in Q1 2019.”

Golden Developing Solutions, Inc. (DVLP), closed the day's trading session at $0.0195, up 8.33%, on 3,133,092 volume with 114 trades. The average volume for the last 3 months is 603,181 and the stock's 52-week low/high is $0.0122/$0.14.

Recent News

chart

Plus Products Inc. (CSE: PLUS) (OTC: PLPRF)

The QualityStocks Daily Newsletter would like to spotlight Plus Products Inc. (CSE: PLUS) (OTC: PLPRF).

Plus Products Inc. (CSE: PLUS) (OTCQB: PLPRF) (the “Company” or “Plus Products”) is pleased to announce that due to strong demand from investors, it has increased the maximum size of the previously announced private placement led by Canaccord Genuity Corp. involving a syndicate of agents (collectively, the "Agents"). Pursuant to the revised terms of the offering, the Company has engaged the Agents to sell, on a “best efforts”, placement basis, up to C$25 million of convertible note units (the “Units”) of the Company at a price of C$1,000 per Unit (the Offering”). Also today, the company was featured in a publication from CFN Media Group looking at significant exposure to the edibles space.

Plus Products Inc. (CSE: PLUS) (OTC: PLPRF) is a branded cannabis-infused products manufacturer of edibles created to support a healthy and active lifestyle. Headquartered in San Mateo, California, PLUS™ concentrates on producing edibles using extracts to ensure compliant, dosable and delicious products that provide a consistent cannabis experience.

First introduced to the market in 2015 to rave reviews, PLUS™ is now one of the top best-selling edible brands in California. PLUS™ operates through a wholly owned subsidiary, Carberry, and has four cannabis-infused gummy candy SKUs (in addition to limited edition SKUs), that are currently sold in over 200 licensed dispensaries and delivery services. All products under the PLUS™ brand are produced in the company’s 12,000-square-foot food-safe cannabis manufacturing facility in Adelanto, California.

PLUS Products shares are currently listed on the Canadian Securities Exchange. PLUS™ raised CAD$20 million through the offering, for which the lead underwriters were PI Financial and Canaccord Genuity. The company intends to use a portion of the IPO proceeds to fund rapid product capacity expansion, factory automation, working capital and new product development.

Operating in the largest adult-use recreational market in the U.S., PLUS Products holds a temporary manufacturing license in California and was one of the first brands to bring fully compliant products to the legal market. California legalized adult use recreational sales on Jan. 1, 2018, and industry analysts expect edible sales there will continue to amass enviable revenues. According to BDS Analytics, edibles made up 18 percent of marijuana retail sales in February 2018 across licensed retailers in California, with PLUS™ products ranking in the Top 10 of edible brands by retail dollar sales.

During the first half of 2018, PLUS Products generated US$2.45 million in sales, a marked improvement over 2017’s US$1.07 million in sales. The company’s established cannabis products are not only compliant with state laws, they are proving to be extremely popular with consumers. Among the PLUS™ product brands are:

  • Blackberry & Lemon RESTORE, an infusion of carefully dosed cannabis with a 9:1 THC to CBD per gummy.
  • Sour Watermelon UPLIFT, a low-calorie gummy crafted from carefully dosed cannabis with an infusion of 5mg THC per gummy.
  • Pineapple & Coconut CBD RELIEF, a tropical flavor gummy made from pure cannabis-derived CBD that is low-calorie, gluten-free and made with kosher ingredients.
  • Sour Blueberry CREATE, a low-calorie gummy infused with hybrid flower containing 5 mg THC.
  • Limited Edition Rose & Vanilla, available at select locations during Winter 2018, these gummies are crafted with 60 mg THC/30 mg CBD per tin.
  • Limited Edition RAINBOW SORBET gummies was created to celebrate Pride during Spring 2018 with a portion of each purchase donated to The Trevor Project, a confidential suicide hotline for LGBT youth.

“We are extremely proud of the products PLUS has brought to market,” remarked Jake Heimark, CEO and cofounder in a statement. “We’ve quickly grown into one of the leading edible brands in California. With the proceeds of this round, we will continue to further our mission: to make cannabis safe and approachable for all types of consumers.”

The PLUS™ team believes that everyone deserves access to consistent, dosable and delicious cannabis products and strives to make that happen. Producing the best infused products at scale requires thoughtful collaboration among experts in many fields. At PLUS™, our team is comprised of Chefs, Chemists, Food Manufacturing Experts, Engineers, Machinists, Visionaries, Creatives, Strategists and others.

Plus Products Inc. (PLPRF), closed the day's trading session at $5.5116, off by 0.64%, on 58,904 volume with 165 trades. The average volume for the last 3 months is 138,169 and the stock's 52-week low/high is $2.81/$6.01.

Recent News

chart

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

ActionStockPicksAgressive StocksBetting On Wall StreetCannabisNewsWireGot Stocks?Got Stock Tips?Green Car StocksGreen Energy StocksGreen On The StreetHomeRunStocksMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireQualityStocks MediaQStocksQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsStock BeatsStocks To Buy NowTerrificStocksTiny GemsTip.usTouchdownStocksDaily ToutTraderPower

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.